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Ischemic heart disease is traditionally seen as a men’s disease and 
publications include predominantly male patients (1). This has resulted 
in extensive knowledge on traditional, mostly male dominated symptoms, 
insights in pathophysiology, response to treatment and outcomes in 
patients with ischemic heart disease. Although the prevalence of ischemic 
heart disease is lower in women than in men, the combined death rates 
from cardiovascular diseases (ischemic heart disease, heart failure and 
strokes) are equal among women and men (figure 1). 
Figure 1 
Percentage of causes of death in men and women in 2013 in the Netherlands.
Source: CBS (www.cbs.nl).
During the last decade, there is increasing evidence that there are 
many differences between men and women in ischemic heart disease, 
although female characteristics have not been extensively studied as male 
characteristics.
Myocardial infarction and particularly ST-Elevation Myocardial Infarction 
(STEMI), is among the most potentially dangerous presentations of 
ischemic heart disease. Differences between men and women regarding 
STEMI start already with the presentation. Next to the main symptoms 
of chest pain, women more often have symptoms of dyspnea, anxiety 
and vasovegetative signs that may be misleading for adequate and timely 
recognition among women themselves and medical workers (2,3). A third 
of the patients with STEMI present with atypical symptoms and patient 
delay in women is often longer due to later recognition (4-6). In general, 
women with STEMI are older with a higher clustering of cardiovascular 
risk factors than men. Also, the distribution of risk factors is different 
between both genders, with a higher risk factor burden in elderly women 
(figure 2). 
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113Figure 2
Cardiovascular risk factors in 3134 men and 997 women presenting with 
STEMI.
Each risk factor between man and women had a p-value of 0.001 or less.
Source: Hochman JS, et al. N Engl J Med. 1999;341; 226–232.
Women more often have hypertension, dyslipidemia and diabetes 
compared to similarly aged men (6,8). Furthermore, the impact of these 
risk factors on ischemic heart disease seems to be age-dependent. In the 
younger age groups (< 65 years) the contribution of smoking to the risk of 
myocardial infarction is relatively higher in women (9). 
Also, there is increasing evidence that hormonal and reproductive status 
is important for the risk of ischemic heart disease in women (10,11). Early 
menopause is associated with a higher risk of ischemic heart disease (12). 
Age at menarche may also be a potential risk factor for ischemic heart 
disease, which is already revealed early in life. Although there is growing 
evidence that menarche is associated with cardiovascular morbidity and 
mortality, it is yet unclear whether women with early menarche are at 
increased risk of STEMI at younger age (13). 
Besides different presentation and different risk profiles, men and women 
with STEMI may have a different pathophysiology. Men more often 
have a ‘traditional’ type I myocardial infarction with a preexisting plaque 
and acute thrombotic coronary obstruction as the cause of STEMI, 
whereas women at younger age more often have a type II STEMI with 
an open coronary artery with often erosive plaques, spasm and endothelial 
dysfunction (14-17). Other types of myocardial infarctions occurring 
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more often in women are spontaneous coronary artery dissection (SCAD) 
and Tako Tsubo cardiomyopathy (TTC) (18). 
SCAD is a rare disease in which the coronary artery develops a tear, causing 
blood to flow between the different layers of the vascular wall. This flow 
forces the layers apart and could result in an obstructed coronary artery 
and STEMI (figure 3). 
Figure 3
Spontaneous coronary artery dissection.
Source: Journal of thoracic disease.
Most patients with SCAD are younger women, leading to the hypothesis 
that SCAD is related to female associated diseases as fibromuscular 
dysplasia (14, 19). As the condition is rare, mostly small case series with 
lack of power are published about the characteristics and treatment of this 
disease (20,21).
115Tako Tsubo cardiomyopathy is a sudden temporary failing of mostly 
the anteroapical muscular wall of the heart (figure 4). Because of the 
characteristic LV contractions, this is also called the apical ballooning 
syndrome. 
Figure 4
Left ventricle “ballooning” in Tako Tsubo cardiomyopathy.
Diastolic LV angiogram
 
         Normal systolic contraction  Apical ballooning in TTC patient 
     with decreased contractions at the arrows 
This acute failing can be triggered by severe emotional stress such as the 
sudden death of a loved one or it can be triggered by physical extremes 
as a bleeding in the brain. It occurs mostly in elderly women (> 60 yrs), 
suggesting a different mechanism between both genders in this STEMI 
mimicking disease. It is important to increase awareness for this diagnosis 
16
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in order to establish the correct diagnosis and treatment of these patients. 
Despite the fact that women more often have open coronary arteries than 
men when presenting with STEMI, (22-24) several reports have observed a 
higher in-hospital mortality after STEMI in women compared to similarly 
aged men, especially in younger age groups (14-16). This discrepancy has 
been called the “gender gap”. There are conflicting results whether this 
difference in mortality is associated with age or with different risk profiles 
between men and women or with gender itself (25-27). 
Women with STEMI may benefit from a more gender sensitive approach, 
not only during presentation and interventions, but also afterwards 
in relation to medical therapy, side –effects of medication and cardiac 
rehabilitation programs. More gender-based research is needed to optimize 
symptom recognition and to understand underlying pathophysiology and 
response to treatment. 
Objectives
The main objective of this thesis is to investigate several gender related 
aspects of STEMI patients. Especially, we studied whether potential 
gender differences are age dependent. We investigated age and gender 
related differences in mortality in STEMI patients, as well as hormonal 
and metabolic factors that potentially influence this relationship. Further, 
we focused on the prevalence and diagnosis of several gender-specific 
subgroups of STEMI patients, related to spontaneous coronary artery 
dissections (SCAD) and Tako Tsubo cardiomyopathy (TTC). 
Inclusion 
All studies include data from the Zwolle ACS database since 1998 until 
as recent as possible at the time of publication except chapter 4 and 8. 
In chapter 4, we included data from 2004 onwards, since HbA1C was 
systematically registered at admittance from 2004 onwards. In chapter 8 
we included data from 2002, since there was only one patient with a Tako 
Tsubo cardiomyopathy (TTC) registered before. 
Outline of this thesis
In chapter 2 we describe the general principles and diagnosis of myocardial 
infarction. The observed clinical differences between men and women are 
the basis for further research.
117In chapter 3 we investigated gender differences in outcomes in a large 
dataset of STEMI patients. In the literature, younger women with 
STEMI have a higher mortality than similarly aged men. The reason 
for this difference is unknown yet. We investigated whether age related 
differences and risk factors contribute to these mortality differences.
One important risk factor for ischemic heart disease that has a higher 
prevalence and mortality in women is diabetes. In chapter 4 we 
investigated whether metabolic differences in STEMI patients with and 
without diabetes contribute to the gender related differences in mortality. 
It is increasingly recognized that factors related to sex hormones are 
important in ischemic heart disease. We investigated whether early 
menarche is an independent risk factor for early STEMI in chapter 5.
Not all STEMI occur due to obstruction of a coronary artery by plaque 
rupture. Age and gender related differences in mortality in patients with 
STEMI may have an explanation in different mechanisms of STEMI 
between man and women. We investigated the characteristics, treatment 
assignment and angiographic outcome in patients with SCAD in chapter 
6. 
Tako Tsubo cardiomyopathy is a STEMI mimicking disease, predominantly 
prevalent in elderly women and rarely in men. We evaluated the occurrence 
of TTC in men and women in a large database of STEMI-patients in 
chapter 7.
The observed number of patients with TTC has changed over the 
past years since TTC was first described in 1991 and first cohorts 
approximately 10 years later. We investigate the occurrence of TTC 
and patient characteristics over the past 12 years in a large population of 
STEMI patients in chapter 8.
Chapter 9 contains the general discussion of the observed findings in 
perspective of our current knowledge on age and gender related differences 
in STEMI patients. Recommendations for future investigations are 
proposed.
18
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Introduction
Fast and adequate treatment of myocardial infarction can make a change 
from an acute event with very high mortality and serious long-term 
morbidity into a condition with low mortality and a very good long-term 
prognosis. However, before treatment can be started, recognition and 
fast diagnosis of myocardial infarction is essential. A number of clinical, 
electrocardiographic, biochemical and imaging tools may be helpful in 
making the diagnosis. In some subgroups, including females, elderly and 
patients with diabetes, it is particularly challenging to the make fast and 
correct diagnosis. 
Typical symptoms
Although patients with acute myocardial infarction may present with a 
variety of symptoms, the classic symptom is chest pain longer than twenty 
minutes in rest. Typical chest pain is a retrosternal heaviness or pressure 
radiating to the left arm, neck or the jaw. (1) Accompanying symptoms 
may be breathlessness, sweating, nausea and vomiting. Symptoms may be 
present at exertion or at rest and are usually longer than 20 minutes present 
and do not or only partially improve on sublingual nitroglycerine spray. 
To discriminate myocardial infarction from other causes of chest pain, 
identification of risk factors can be helpful. The presence of older age, 
diabetes, smoking, hypercholesterolemia, obesity positive family history, 
peripheral artery disease, renal insufficiency or previous coronary artery 
disease, increases the likelihood of myocardial infarction. (1) However, 
this can also be dangerous, and may be the cause that in young women 
the diagnosis is missed. The importance cannot enough be overstated, 
both for general population and all healthcare workers, that every patient 
with unexplained chest pain should be evaluated to exclude myocardial 
infarction.
Atypical symptoms
Recognizing atypical symptoms as signs of myocardial infarction is 
important, since one third of patients presenting with myocardial infarction 
do not have chest pain, and one fifth do not have ischemic symptoms at 
all. In this case myocardial infarction can be only diagnosed by ECG, 
laboratory results or imaging. (2) So called ‘silent’ myocardial infarctions 
are more common in women, diabetics and elderly patients. Also, these 
patients are less likely to be diagnosed with myocardial infarction at the 
223
time of admission. (3) Atypical symptoms in patients presenting with 
myocardial infarction is common. A patient with atypical chest pain may 
present with a sharp or burning pain that is reducible with palpation or 
localizable with one finger in other areas of the upper body than the chest. 
Atypical chest pain is more prevalent in elderly, patients with diabetes and 
women.
Symptoms in women 
Women are less likely than men to present with typical chest pain in 
myocardial infarction. They present more often with fatigue, sleep 
disturbance, weakness and shortness of breath, but these symptoms are 
of course not specific. (4,5) The higher prevalence of atypical symptoms 
in women compared to men presenting with myocardial infarction, is 
probably the most important reason for the longer patient delay in women. 
(3) Also, myocardial infarction may be unrecognized more often in women 
compared to men because of the more atypical presentation in women. 
Furthermore, awareness by both health care workers and patients may be 
less in symptomatic women, because in the general population and even 
healthcare workers it is still thought that myocardial infarction is a disease 
of men. This is difficult to “treat”, the effects of national campaigns to 
increase awareness in women were not clear. (6) However, a local initiative 
was more successful, particularly decreasing door-to-table time delay in 
women. (7)
Key terms:
- Classic symptoms are retrosternal pressure radiating to the left arm, 
neck or the jaw.
- In every patient with unexplained chest pain, myocardial infarction 
should be excluded.
- Several subgroups, particularly women, may present with atypical 
symptoms.
- More efforts are necessary to decrease time delay in women.
Physical examination
Physical examination is almost normal in most patients with myocardial 
infarction, but is important to identify hemodynamic instability and sings 
of heart failure and to exclude other causes as pneumothorax, which can 
even be accompanied by transient ST-segment elevation on ECG. (8) 
24
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Other non-cardiac causes of chest pain that can be identified by physical 
examination include valvular heart disease, aortic dissection, thoracic 
muscle pain, pneumonia or a gastro intestinal origin. Body temperature, 
blood pressure differences in limbs, heart murmurs, abnormal lung 
auscultation and pain on palpation are therefore important to asses in 
every patient with suspected myocardial infarction.
Electrocardiography 
Electrocardiography (ECG) has a key role in diagnosing myocardial 
infarction and to discriminate between ST elevation myocardial infarction 
(STEMI) and non ST elevation myocardial infarction (NSTEMI), and 
should be performed in every patient with chest discomfort. 
ECG changes in STEMI 
ECG changes have prognostic importance, and can be used for risk 
stratification. ST-elevation myocardial infarction is defined as a new 
elevation, during at least 20 minutes, in two contiguous leads with ≥ 2 
mV in men and ≥ 1.5 mV in women. In precordial leads (V2-V3) 1 mm 
ST-elevation is diagnostic for myocardial ischemia. (9) The localisation 
of ischemia can be diagnosed from which of the leads show ST-elevation. 
(Table 1) An anterolateral infarction is depicted in figure 1 as an example. 
In the first hours of myocardial infarction, T- tops become more positive 
followed by a ST-elevation. Reciprocal ECG ST depression in the other 
leads may be observed. After a few hours after initiation of myocardial 
ischemia, myocardial necrosis and therefore pathological Q-waves 
(defined as one third of the total QRS) occur and QS wave forms may 
be present. T waves become negative. In eighty to ninety percent of 
patients, pathological Q waves and negative T-waves stay present on the 
ECG. If ST-elevations are present six weeks after initiation of myocardial 
infarction, an aneurysm cordis might be present. (10) In case of a STEMI, 
also risk stratification can be made with an ECG: the higher the sum of the 
ST elevation the higher the mortality. (11) 
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Table 1
Localisation of myocardial ischaemia and ECG changes
Localisation myocardial ischemia Leads of elevation ST depression
Anterior V2-V5 II, III, aVF
Septal V1-V3 II, III, aVF
Lateral I, aVL, V6 II, III, aVF
Inferior II, III, aVF I, aVL, V1-V4
Posterior V7-V9 V1-V3 (mirrored)
Right ventricle (often in combination 
with inferior)
V4R, V1, V2 I, aVL
Figure 1
Electrocardiographic pattern of anterolateral myocardial infarction.
 
10mm/mV, 25mm/s
Left bundle branch block
Although it is difficult to make a diagnosis of myocardial infarction in 
patients with a left bundle branch block, a new left bundle branch block 
is a strong argument for ischemia. Furthermore, the criteria as defined 
by Sgarbossa can be used to diagnose myocardial infarction: ST elevation 
> 1mV concordant with the direction of the QRS complex (score 5), 
ST depression > 1mV in V1-V3 (concordant with the direction of the 
QRS complex) (score 3) or ST elevation > 5mV disconcordant with the 
direction of the QRS complex (score 2). With a sum of the scores of at 
26
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least 3, the diagnosis of myocardial infarction can be made with ninety 
percent specificity. (12)
Not all ST-elevations on the ECG are due to ischemic myocardium. In 
patients with peri(myo) carditis for instance, ST-elevation can be present 
diffusely in the ECG. In this case, an echocardiogram can aid to diagnose.
ECG changes in NSTEMI 
A non ST-elevation myocardial infarction presents with ST segment 
depressions, T wave inversions or no ECG changes at all. These ST-T 
changes might be in one or two leads or be diffusely present on the ECG. 
It is an indication of myocardial ischemia, if there are dynamic changes in 
the ST-T segment. Unstable angina is distinguished from NSTEMI with 
cardiac biomarkers. If there are no ST-segment changes on the ECG, it is 
important to asses a right-sided and a posterior ECG, because myocardial 
ischemia in these locations is not well represented in the normal ECG and 
therefore, a STEMI in these locations might be missed. (13) In patients 
with a large area at risk, for instance a lesion of the left main artery or in 
all three main coronary arteries, ST elevations may only be present in V1 
and ST depressions may be present in the other leads. 
ECG indicating old myocardial infarction
Patients with previous STEMI’s can have pathological changes such as Q 
waves on the ECG. NSTEMI patients usually do not have pathological Q 
waves on the ECG. The localisation of pathological Q waves is usually in 
the leads that the ST-elevation occurred in. However, not all pathological 
Q waves are specific for previous myocardial infarction. Examples of non 
ischemic pathological Q waves are wrongly placed ECG leads, a left bundle 
branch block, left and right ventricular hypertrophy, pulmonary embolism, 
hypertrofic cardiomyopathy and Wolf Parkinson White syndrome with an 
accessory electrical abnormal pathway.
Pre-hospital care 
Most patients presenting with myocardial infarction are being transported 
by an ambulance. Not only fast transportation is important, but early 
diagnosing, triage and treatment of myocardial infarction have shown to 
reduce mortality in STEMI patients. (14) Therefore, ambulances should 
be fully equipped with ECG and defibrillators and ambulance teams 
should be trained to identify STEMI on the 12-lead ECG. (15) Once the 
227
STEMI is identified, the nearest PCI hospital should be informed of the 
expected time of arrival. 
Key terms:
- An ECG should be performed in all patients with chest discomfort 
and can differentiate between ST elevation and non-ST elevation 
myocardial infarction.
- With an ECG, the diagnosis can be made, but a normal ECG cannot 
exclude myocardial infarction.
- In case of left bundle branch block, diagnosis of myocardial infarction 
is more difficult, but should be considered if LBBB is new.
- Ambulance teams must be trained to diagnose electrocardiographic 
signs of infarction.
Biomarkers
There are several biomarkers indicating myocardial infarction. Troponin 
is the preferred biomarker to make a final diagnosis because the high 
sensitivity and specificity as compared to other biomarkers High 
sensitivity troponin is even more sensitive resulting in less false negative 
test results. Although cardiac biomarkers reflect myocardial necrosis, the 
aetiology of this necrosis might still be unknown. Stable elevated cardiac 
biomarkers might be present in patients with a tachycardia, bradycardia, 
renal failure, inflammatory diseases, extreme exertion and chronic heart 
failure. Therefore, myocardial infarction is only diagnosed in patients with 
a clinical setting of myocardial infarction in combination with elevated 
biomarkers. 
A typical rise of the troponin value is a strong argument for myocardial 
ischemia and infarction. (9) Especially as previously described, when there 
are no ST-elevations on the ECG, elevation of cardiac biomarkers is the 
only parameter to distinguish patients with NSTEMI from a patient with 
an unstable angina. Troponin levels usually begin to rise two to three 
hours after onset of myocardial infarction. Therefore, in patients without 
ST-elevation on the ECG and a second troponin at least three hours apart 
should be assessed to detect myocardial ischemia. (16) If a patient have 
had symptoms for at least six hours prior to admission, only one troponin 
measurement suffices to detect myocardial ischemia.
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CK and to minor extend, CK-MB, are less specific or sensitive than high 
sensitive troponins. These parameters however can be used to estimate 
the infarct size. 
LDH is mostly used for the estimation of the onset of myocardial 
infarction. It is a cardiac biomarker that rises ten hours after the onset 
of a myocardial infarction and peaks at sixty-four to eighty hours. When 
LDH is elevated, it is generally accepted that the myocardial infarction is 
present for at least ten hours. 
Key terms:
- Cardiac biomarkers can exclude acute myocardial infarction, but 
should be followed for hours.
- Cardiac biomarkers have a key role in diagnosing non-ST elevation 
myocardial infarction
- High sensitive troponin is the first choice biomarker
Non-invasive imaging
In the acute setting in patients with suspected myocardial infarction but 
without electrocardiographic evidence of infarction, echocardiography 
should be strongly considered to aid the diagnosis of myocardial infarction. 
It can differentiate between cardiac and non-cardiac, ischemic and non-
ischemic (as pericarditis) heart disease, and may give information about 
the ischemic region, the extend of ischemia and whether there is an old 
myocardial infarction. If wall motion abnormalities are present in a regional 
segment and the myocardial thickness is reduced, an old myocardial scar 
may be present. (17) Furthermore, if there are wall regional wall motion 
abnormalities without reduction of the wall thickness, myocardial ischemia 
should be considered. Echocardiography is an important diagnostic tool 
to assess alternative diagnosis of the symptoms like peri(myo)carditis, 
cardiomyopathy, pulmonary embolism, aortic dissection and valvular 
stenosis or insufficiency. (18) If a patient is or become hemodynamically 
instable, complications from a myocardial infarction like pericardial effusion 
due to ventricular rupture or massive mitral insufficiency after papillary 
muscle rupture can be diagnosed adequately with echocardiography 
(19). Echocardiography is not validated to detect myocardial ischemia. A 
direct method to observe myocardial ischemia is radionuclide imaging. 
Several tracers allow viable myocardium to be imaged and differentiated 
from ischemic myocardium. However, small areas of infarction may be 
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undetected. Furthermore, ischemia is detected in relation to non-ischemic 
myocardial infarction, so if almost all of the myocardium is ischemic, the 
result can be false negative. 
Magnetic resonance imaging has in theory the same application as 
echocardiography with a high spatial resolution. In clinical practice 
however, MRI is quite cumbersome and not practical in the acute setting. 
Key terms:
- In the acute phase of patients with chest discomfort, echocardiography 
is important in patients with a non-diagnostic ECG, particularly if 
complaints sustain.
- Other modalities of non-invasive imaging, including radionuclide 
imaging and MRI can be used in the chronic phase.
Coronary angiography 
In STEMI, coronary angiography is in many patients obtained urgently, 
shows the infarct related vessel, the presence of multivessel disease and is 
often combined with primary percutaneous coronary intervention. Also in 
patients with persisting chest pain despite optimal medical treatment or 
patients with complications (unstable arythmia’s, acute mitral regurgitation, 
cardiogenic shock and ventricular septal defect) coronary angiogram is 
performed urgently if possible. The timing of coronary angiography for 
patients with NSTEMI less clear. (20)
Key terms:
- In STEMI, invasive coronary angiography can confirm the diagnosis 
and preferably is followed by primary PCI if indicated.
- In non-STEMI an invasive approach should be considered in most 
patients, although the timing of angiography is less clear.
Differential diagnosis of myocardial infarction CARDIAC
In patients with a clinical suspicion of myocardial infarction, other 
differential diagnosis should also be considered. Patients with pericarditis 
can present with sharp chest pain, increasing with sitting up or leaning 
forward and pericardial friction rub with auscultation. The ECG can 
present with diffuse ST-elevation in all ECG leads, mimicking a STEMI 
with involvement of all coronary arteries, which rarely happens. Also, PR-
segment depression on the ECG might be present. Echocardiography 
30
2
can be used to visualise pericardial effusion, which is present in 60% 
of pericarditis patients. (21) Or visualise wall motion abnormalities, to 
improve the probability of myocardial infarction. 
Tako Tsubo or apical ballooning syndrome is a cardiomyopathy induced 
by emotional stress. An acute and reversible ventricular dysfunction can be 
observed and ECG changes are mostly similar of an anterior myocardial 
infarction. Notably with Tako Tsubo, there are no coronary abnormalities. 
Mostly post menopausal women are affected by this cardiomyopathy. (22)
NON CARDIAC
Chest pain can be induced by other organs or tissue in the chest. 
Muscosceletal chest pain is a vast proportion of patients presenting with 
chest pain to the emergency ward. (23) Muscosceletal pain might be 
induced by palpation on the sternum or movement of the upper limbs. 
Oesofageal reflux is another cause of acute chest pain in patients. (24)
Pulmonary embolism is another important differential diagnosis in 
patients with a clinical suspicion of myocardial infarction. Patients might 
present with chest pain, increasing with respiration. The ECG changes 
in pulmonary embolism may be a right bundle branch block, Q waves 
(pseudo infarction pattern) ST-elevations or depression in the precordial 
leads. (25) Also in this situation, echocardiography might be very valuable 
to visualise elevated right sided pressures and dilatated right ventricle, 
sometimes present in pulmonary embolism or wall motion abnormalities 
in myocardial infarction.
In case of abdominal pathology for instance with an ileus or pancreatitis, 
ECG and even clinical presentation might mimick a STEMI. (26)
Figure 2
Differential diagnosis in patients with a clinical suspicion of myocardial 
infarction.
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Key terms:
- In the differential diagnosis of myocardial infarction, a structured 
approach should be performed.
- First step in the differential diagnosis is to differentiate between 
cardiac and non-cardiac causes.
DEFINITIONS OF DIAGNOSES
STEMI
In patients in the clinical setting of myocardial infarction and ST-elevation 
on the ECG suggestive of myocardial infarction or (presumed) new left 
bundle branch block.
NSTEMI
- Typical rise and fall of cardiac biomarkers  (Troponin, CK, CK-MB, 
LDH) with at least one of the following:
o Symptoms of ischemic symptoms
o Development of pathological Q waves on the ECG
o ECG changes indicative of new ischemia (negative ST elevation 
or depression, LBTB)
o Imaging evidence of new regional wall motion abnormality or 
new loss of viable myocardium
- Evidence of fresh thrombus at coronary angiography or autopsy
- Pathological findings of a acute myocardial infarction
Prior myocardial infarction is defines as:
- development of new pathological Q waves on the ECG with or 
without symptoms. Biochemical markers may have normalized.
- Imaging evidence of a thin and a regional loss of myocardium that 
fails to contract in the absence of non-ischemic cause.
- Pathological findings of a prior myocardial infarction. (9)
When diagnosing a patient without ST-elevation the ECG the, it is 
important to asses possible rise and fall of the troponin, because NSTEMI 
should be differentiated from unstable angina pectoris by a relative or 
absolute increase in troponin values. (27) Other causes of elevated cardiac 
biomarkers not caused by coronary artery disease include: tachycardia, 
bradycardia, myocarditis, chronic heart failure, impaired kidney function. 
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(15) In some of these cases, even a rise and fall of the troponins can be 
observed. Therefore, careful anamnesis is essential.
Chapter summary
- As treatment can dramatically change prognosis of myocardial 
infarction (MI), fast and accurate diagnosis is essential.
- There are several tools in diagnosing MI, but everything starts with 
recognizing suspected symptoms.
- Women, the elderly and diabetics more often have atypical symptoms.
- Clinical examination is important to diagnose heart failure and exclude 
noncardiac causes.
- Electrocardiographic changes play a key role in diagnosing myocardial 
infarction and in differentiating between ST-segment elevation MI 
and non-ST-segment elevation MI.
- Elevated cardiac biomarkers are particularly essential in those without 
ECG changes and may have prognostic importance.
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Abstract
Aim: Poorer outcomes in women with ST-elevation myocardial 
infarction (STEMI) are often attributed to gender differences in baseline 
characteristics. However, these may be age dependent. We examined the 
importance of gender in separate age groups of patients with STEMI 
undergoing primary percutaneous coronary intervention (PPCI).
Methods and results: Data of 6746 consecutive patients with STEMI 
admitted for PPCI between 1998 and 2008 in our hospital were evaluated. 
Age was stratified into two groups, <65 years (young group) and ≥65 years 
(elderly). Endpoints were enzymic infarct size as well as 30-day and 1 
year mortality. We studied a total of 4991 (74.0%) men and 1755 (26.0%) 
women; 40% of women were <65 years and 60% of men were <65 years 
of age. In the elderly group (≥65 years), women had more frequently 
diabetes and hypertension while they smoked less frequently than men. 
Younger women smoked more often than similarly aged men and had 
more hypertension. At angiography, single-vessel disease and TIMI 3 
flow before PPCI was more present in younger women than men, whereas 
these differences were not found in the older age group. Patient delay 
before admission was shorter in men at all ages, while women had lower 
creatine kinase levels. Younger women had a higher mortality after 30 
days (HR 2.1, 95% CI 1.3−3.4) and at 1 year (HR 1.7, 95% CI 1.2−2.6), 
whereas in the older age group women mortality rates were higher at 30 
days (HR 1.5, 95% CI 1.1−2.0) but not at 1 year (HR 1.2, 95% CI 0.9−1.5). 
After multivariate analysis, 1-year mortality remained significantly higher 
in women at younger age (HR 1.7, 95% CI 1.1−2.5). Patient delay before 
admission was shorter in men in both age groups. Creatine kinase levels 
were in both age groups higher in men.
Conclusions: Differences in mortality between men and women with 
STEMI treated with PPCI are age dependent. Although young women 
have less obstructive coronary artery disease and more often TIMI 3 flow 
before PCI (suggesting a lower risk), survival was worse compared to 
similarly aged men. Women had a longer patient delay compared to men, 
but this was not related to gender-specific mortality.
Keywords
Acute coronary syndrome, age, gender, STEMI, women
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Introduction
Over the past decade, several reports on gender differences in prognosis 
after primary percutaneous coronary intervention (PPCI) in ST-segment 
elevation acute myocardial infarction (STEMI) have revealed conflicting 
results (1–6). Higher in-hospital mortality in women was often attributed 
to a longer patient delay before admission, older age, a higher clustering 
of cardiovascular risk factors, lower use of invasive and medical treatment, 
and more bleeding com-plications after interventions (6–13). Remarkably, 
especially in the younger age groups, women had a worse outcome 
compared with age-matched men (14–18). This may be related to a variety 
of factors such as gender differences in plaque composition, differences 
in thrombotic activity, and a higher prevalence of microvascular disease 
in younger women (19–22). However, as most previous studies did not 
stratify into age groups, it is less clear whether these gender differences in 
prognosis after STEMI are age dependent. Some studies did stratify on age 
but included patients with both STEMI and non-STEMI, representing 
a heterogenous population with acute coronary syndrome (6,23). In our 
present study from the Zwolle Myocardial Infarction Study Registry, we 
compare outcomes between women and men with STEMI, all referred for 
PPCI, within two different age groups.
Methods
Population
From January 1998 to January 2008, individual data from all STEMI 
patients who were considered for PPCI at our centre, were prospectively 
recorded in a dedicated database. Patients were diagnosed with STEMI 
if they had chest pain longer than 30 minutes and ECG changes with ST 
elevation greater than 2 mm in at least two precordial leads or greater 
than 1 mm in the limb leads. Cardiac biomarkers were elevated in all 
patients. According to the protocol, all patients received 500 mg aspirin 
and 5000 IU heparin intravenously before the PPCI procedure. Primary 
PCI was performed using standard techniques, if the coronary anatomy 
was suitable for intervention. Success rate of the procedure was assessed 
according to TIMI (24) classification, in which a grade 3 blood flow within 
the infarct related artery and a myocardial blush grade (25) 2 or 3 were 
considered to be adequate. The classification for bleeding (major and 
minor) was used according to the definition of the TIMI study group. 
Where appropriate, patients were treated with drug therapy, including 
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aspirin, clopidogrel, heparin, beta-blockers, ACE, angiotensin-converting 
enzyme (ACE) inhibitors, and lipid-lowering medication. Glycoprotein 
IIb/IIIa inhibitors were used according to the discretion of the treating 
cardiologist.
Laboratory measurements
According to the hospital protocol, blood sampling for creatine kinase 
(CK) and CK-MB levels was done at baseline and 8, 16, and 24 hours 
after PPCI. Infarct size was also estimated according to measurements of 
cumulative enzyme activities using lactate dehydrogenase (LDH) as the 
reference enzyme, as we have previously described in detail (26).
Data collection
Data were divided into four groups according to gender and age <65 years 
and ≥65 years. Information on demographic parameters, risk factors, 
laboratory values, angiographic variables, and medication was derived 
from the patient files. Follow-up information was obtained from the 
outpatient files, the general physicians, or by direct telephone interview 
with the patients and was prospectively obtained using pre-defined time 
intervals of 30 days and 1 year with telephone interviews performed by 
independent research nurses, who were not involved in patient treatment. 
MACE was defined as the combination of death, myocardial infarction 
(MI), percutaneous coronary intervention (PCI), and/or coronary artery 
bypass surgery (CABG). Recurrent MI was diagnosed when there was 50% 
increase of CKMB from a previous peak value, followed by a subsequent 
rise to a level exceeding the upper limit during hospital stay or recurrent 
hospitalization with the diagnosis MI. Bleeding was defined as intracranial 
or overt bleeding with a decrease of haemoglobin ≥3 g/dl (≥1.9 mmol/l) 
or >10% decrease in haematocrit within 48 hours, and, if a bleeding site 
was not identified >4 g/dl decrease in haemoglobin or >12% decrease in 
haematocrit within 48 hours.
Statistical analysis
Statistical analysis was performed using SPSS version 18.0 (SPSS, Chicago, 
IL, USA). Continuous data were expressed as median and interquartile 
range and categorical data as number and percentage, unless otherwise 
indicated. Tests for significance were two-sided, with an α of 0.05. Cox 
proportional hazard regression was performed to estimate hazard ratios for 
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mortality. Proportional hazard assumption was evaluated both graphically 
as with the Schoenfeld residual (27). As proportional hazard assumption was 
not respected for gender, Killip class >1 and multivessel disease in the older 
age group, we therefore employed a time-dependent covariate. Mortality 
was reported with hazard ratio (HR) and 95% confidence intervals (CI). 
Baseline characteristics with a p-value of <0.1 and significantly values in 
the different age and gender groups with univariate analysis were analysed 
with stepwise regression and included in the final multivariate model. We 
limited the variables to four per group to prevent overfitting. Variables 
in the multivariate model were age, multivessel disease, Killip class, and 
hypertension. Medication use was analysed using landmark analysis at 
discharge and 30 days. Gray’s test was used for analysis of competing risks 
to analyse re-PCI, re-CABG, and re-MI with mortality as a competing 
event (28).
Results
Data from 6746 patients with STEMI who underwent a PPCI between 
1998 and 2008 in our hospital were evaluated, consisting of 4991 (74%) 
men and 1755 (26%) women. Baseline characteristics for men and women 
in age groups of <65 years (young) and ≥65 years (elderly) are presented in 
Table 1; 40% of the women were <65 years old and 60% of the men were 
<65 years old.
Hypertension was more prevalent in women within both age groups 
than in men. In younger women, a positive family history and current 
smoking were significantly more present, while at older age women had 
more hypertension and diabetes. In both age groups, total ischaemic time 
and patient delay before hospital admission were significantly longer 
in women, whereas there was no gender difference in in-hospital delay 
from admission to first balloon inflation. Angiographic data showed less 
obstructive coronary artery disease in younger women compared with 
younger men, with a higher TIMI 3 flow at angiography and a lower CK 
release (Table 2). In the older age group, the occurrence of multivessel 
disease and TIMI-3 flow before PPCI were not significantly different 
between men and women. The TIMI flow and blush grade 3 post PPCI 
was not significantly different between men and women.
Overall, mortality at 30 days (HR 2.1, 95% CI 1.6−2.5) and at 1 year (HR 
1.6, 95% CI 1.3−1.9) was higher in women than in men. The median 
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duration of follow up in the younger group was 403 (396−409) days and 
in the older group 395 (389−400) days. The missing patients at 1 year in 
the younger group were 36 women and 187 men and in the older group 
73 women and 146 men. At 1 year, 454 patients deceased in the total 
population. In the younger group 36 women and 87 men died and in the 
older group 124 women and 207 men died. At univariate analyses, women 
compared to men in the younger age group had a significantly increased 
risk of mortality both 30 days (HR 2.1, 95% CI 1.3−3.4) and at 1 year (HR 
1.7, 95% CI 1.2−2.6). Mortality at 30 days was also higher in women in 
the older age group (HR 1.5, 95% CI 1.1−2.0). There was no difference, 
however, in mortality between both genders at 1 year (HR 1.2, 95% CI 
0.9−1.5) (Table 3, Figure 1). At univariate analysis common predictors for 
mortality in elderly men and woman were age, Killip class, and previous 
history of cerebrovascular accident. In the younger age group, adverse 
predictors were age, Killip class, and the presence of multivessel disease. 
Hypertension was a common predictor for mortality in elderly women 
and in young men. Multivariate analyses, adjusting for multivessel disease, 
Killip class, age, and hypertension confirmed these findings in the younger 
age group (HR 1.7, 95% CI1.1−2.6). In the older age group, the hazard 
ratio for 1-year mortality was comparable in women and men (HR 1.0, 
95% CI 0.8−1.4) (Figure 2). In the model with age and gender as an 
interaction term, 1-year mortality remained significant (HR 0.97, 95% CI 
0.95−0.99). Re-MI, re-PCI, and re-CABG were analysed with the Gray’s 
test for comparison of cumulative incidence curves between men and 
women for 30-day and 1-year mortality. Mortality remained significant 
between men and women in both age groups at 30 days and in the younger 
group at 1 year.
Medication use at various time intervals is depicted in Table 4. Women were 
using more often insulin and diuretics at discharge, except in the younger 
age group. The use of aspirin, beta-blockers, statins, and ACE inhibitors 
was comparable in all 12 subgroups, except for higher rates of ACE 
inhibitors use at discharge in elderly men. Clopidogrel has been routinely 
used in our hospital since 2004. Its use in the acute phase was comparable 
between women and men in both age groups. Also glycoprotein IIb/IIIa 
inhibitor use in the acute phase was comparable between women and 
men in both age groups (Table 4). Of the 367 patients in our study who 
initially received conservative treatment, 102 patients had non-obstructive 
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coronary artery disease and 23 patients were treated with PCI during the 
same hospitalization. In two patients it was not possible to pass the wire 
through the stenosis whereas in three patients, the PCI was performed 
after several days, after an initially conservative approach. One patient had 
an older infarction and PCI was performed after demonstrating residual 
ischaemia by non-invasive testing. Two patients were referred from other 
hospitals after conservative treatment for unknown reasons. In 10 patients 
no culprit vessel was treatable due to too small vessel size and in the 
remaining five patients no details were available, and 243 patients were 
treated conservatively because PCI was not indicated.
Discussion
In our present study in patients with STEMI, treated with PPCI, we 
found that 1-year mortality was higher in women than in men in the age 
group <65 years. Whereas in the older age group mortality was higher 
at 30 days in women, there was no gender difference at 1 year. Several 
other single-centre and multicentre studies have shown higher in-hospital 
mortality rates in women compared to men. These differences are often 
attributed to their higher age and clustering of more CV risk factors 
(9–11). In some studies, gender differences in treatment and higher 
rates of in-hospital complications in women are considered as possible 
causes for their higher mortality rates (5,10). In our study, we found 
that differences in mortality between women and men persisted after 
correction for confounders by multivariate analysis. Treatment strategies 
in the acute setting were standardized and therefore comparable between 
both genders. It is alarming, however, that, although younger women 
had a lower risk profile at baseline, with more TIMI 3 flow before PCI 
and less multivessel disease, they had a higher mortality than similarly 
aged men. There may be several explanations for this adverse prognosis 
in women. First, despite their increased mortality rates at 30 days and 
at 1 year, younger women undergo less often a re-PCI than men (Table 
3). Almost half of all re-PCI procedures were performed within the first 
30 days, in which time most gender-related mortality differences are also 
seen. With our data, we cannot demonstrate whether the lower number 
of re-PCIs in younger women has had prognostic importance, and this 
should be examined carefully in future studies.
The total enzymatic infarct size (as measured by CK) was lower in young 
women compared to similarly aged men. We found no gender differences 
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in LDH values within both age groups. This may partly be related to 
the usually smaller body weight in women, although detailed information 
on body mass index is lacking in our study. Further, since women have a 
longer patient delay in both age groups compared to men and therefore 
hypothetically present more often after the peak of the CK levels (2−12 
hours), this may possibly have resulted in lower CK levels. Secondly, 
because men have a shorter patient delay, they are more likely to be 
discharged before the peak LDH levels (24−48 hours) as most patients 
were discharged shortly after the CK peak. It is noteworthy that longer 
patient delay in women may be related to the absence of chest pain. 
However, patient delay was not a strong predictor for gender-specific 
mortality neither in a recent large study (29) nor in our study. In our study 
cohort, we have no data on type of chest pain/discomfort.
Our present findings confirm the existence of the so called ‘gender paradox’ 
in young women with STEMI (13,14,30). Several mechanisms may be 
involved to explain this phenomenon. First, we found important gender 
differences in baseline characteristics within the younger age group with 
a higher percentage of current smokers in women (67%) in comparison 
with men (60%). Smoking increases the risk of an acute MI relatively more 
in young women than in young men (31,32). Cigarette smoking increases 
oxidative stress and promotes the release of vascular inflammatory markers 
leading to a decrease in endothelial function (33). This counteracts the 
protective vasodilating effects of endogenous oestrogens in women before 
menopause (34) Although data are lacking in our cohort on the percentage 
of women that were using oral contraceptives, its use is common in 
premenopausal women in the Netherlands and also enhances the risk 
of arterial thrombosis and MI (35,36) In contrast, the use of hormone 
replacement therapy after menopause is rare in our country. In addition, 
data on previous gynaecology operations, endogenous oestrogen status, 
or menopausal status are lacking in our patients while this has shown 
to be relevant in women (37). Evidence is increasing that hysterectomy, 
especially before the age of 50 years, interferes with an increased risk of 
cardiovascular disease (38).
Gender-related differences in the pathophysiology of STEMI in women 
at younger age may also increase mortality. At younger age, the occurrence 
of plaque rupture with subsequent thrombosis is more common in men, 
while plaque erosions with microvascular embolization are relatively 
more frequently reported in women (19–21). In pathology studies, it is 
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shown that erosive plaques have a lower degree of critical stenosis with a 
greater maturation of thrombus material compared to ruptured plaques, 
especially in younger women (19,39). Furthermore, if plaque ruptures 
occur, they are more related to thrombus formation in women than in 
men.40 Women exhibit acute coronary syndrome with open coronary 
arteries more frequently than men (41,42). Non-obstructive coronary 
artery disease with microvascular dysfunction and abnormal coronary 
reactivity may also be relatively more important in women with STEMI 
and affect prognosis negatively (43).
In our study, TIMI–flow post PPCI and myocardial blush grades, as 
indicators of reperfusion, were comparable between women and men in 
both age groups. This is in concordance with data from previous studies 
(44).
We found that main gender differences in medication use after STEMI 
were higher rates of insulin and diuretics use in women. This can be 
explained by the higher prevalence of hypertension and diabetes mellitus. 
Limitations are that our patients were included during a 10-year time 
period in which PPCI procedures and medication given during this 
procedure were due to some changes. Also, although clopidogrel was 
prescribed for 1 year in all patients, we do not have detailed information 
about eventually discontinuation of clopidogrel, and we can not exclude 
that discontinuation may have affected late stent thrombosis and re-MI 
(45,46). In conclusion, in our single-centre cohort with STEMI patients, 
we found that younger women have a higher mortality than similarly aged 
men, despite the presence of less obstructive coronary artery disease and 
better TIMI 3 flow before PCI. More data are needed to explain these 
differences to improve prognosis in younger women.
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Table 1
Baseline characteristics according to gender and age.
Women
<65 years 
n=708
Men
<65 years 
n=3006
p-value Women
≥65 years 
n=1047
Men
≥65 years 
n=1985
p-value
Age (years) 55 
(48−61)
54 
(48−60)
0.25 75 
(70−80)
72 
(68−77)
<0.001
History of:
MI 38 (5) 224 (8) 0.05 77 (7) 301 (15) <0.001
CABG 11 (3) 56 (2) 0.58 35 (3) 115 (6) 0.003
PCI 19 (3) 162 (5) 0.003 57 (6) 195 (10) <0.001
Stroke 17 (2) 50 (2) 0.18 33 (3) 110 (6) 0.003
Risk factors
History of 
hypertension
245 (35) 799 (27) <0.001 495 (48) 690 (35) <0.001
History 
of DM
70 (10) 235 (8) 0.069 214 (21) 251 (13) <0.001
Hyper-
lipidaemia
137 (20) 701 (25) 0.023 204 (21) 372 (20) 0.69
Positive 
family 
history
375 (55) 1400 (48) 0.001 314 (32) 554 (29) 0.22
Current 
smoking
468 (67) 1766 (60) <0.001 236 (23) 565 (30) <0.001
Admission data
Killip class 
>1
49 (7) 162 (5) 0.10 116 (11) 179 (9) 0.068
Ischaemic 
time (min)
218 
(160−339)
200 
(148−296)
0.001 237 
(178−364)
220 
(164−315)
<0.001
Patient delay 
(min)
165 
(110−285)
150 
(100−240)
<0.001 180 
(120−291)
165 
(110−254)
<0.001
Door-to-
balloon time 
(min)
45 
(30−64)
44 
(30−66)
0.32 48 
(33−73)
46 
(33−73)
0.12
Values are median (IQR) or n (%).
CABG, coronary artery bypass surgery; DM, diabetes mellitus; MI, myocardial infarction; 
PCI, percutaneous coronary intervention. 
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Table 2
Angiographic findings and treatment strategies according to gender and age.
Women
<65 years 
n=708
Men
<65 years 
n=3006
p-value Women
≥65 years 
n=1047
Men
≥65 years 
n=1985
p-value
Multi-
vessel 
disease
33.2 44.7 <0.001 59.7 61.6 0.31
Initial 
treatment
0.36 0.24
Conser-
vative
5.6 5.4 6.5 5.3
PPCI 91.9 91.1 89.0 89.4
CABG 2.5 3.5 4.5 5.3
Stent 
placement
75.2 74.8 0.85 66.4 69.7 0.07
Infarct related vessel
Left main 1.2 0.8 0.34 0.9 1.3 0.58
Graft 0.7 0.8 0.76 1.8 3.3 0.02
LAD 43.9 43.9 0.97 45.2 45.4 0.91
RCA 41.3 38.9 0.25 40.7 36.7 0.04
Cx 12.9 15.6 0.07 11.4 13.4 0.12
TIMI-3 
before PPCI
24.6 19.9 0.008 19.7 18.4 0.42
TIMI-3 
after PPCI
92.1 91.7 0.72 87.3 87.8 0.73
TIMI 0−1 
after PPCI
3.7 3.2 0.48 4.9 4.3 0.51
Blush grade 
3 post PPCI
51.9 49.7 0.38 40.8 41.3 0.85
CK max. 1400, 
(581−2854)
1691, 
(685−3398)
0.001 1268, 
(549−2500)
1514, 
(640−3008)
0.001
LDH max. 489, 
(297−827)
485 
(272−837)
0.80 503 
(305−872)
491 
(299−792)
0.24
Values are median (IQR) or %.
CK, creatine kinase; Cx, circumflex; LAD, left anterior descending; LDH, lactate 
dehydrogenase; PPCI, primary percutaneous coronary intervention; RCA, right coronary 
artery; TIMI, Thrombolysis in Myocardial Infarction.
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Table 3
Clinical outcomes according to gender and age.
Women
<65 years 
n=708
Men
<65 years 
n=3006
p-value Women
≥65 years 
n=1047
Men
≥65 years 
n=1985
p-value
Bleeding 
(<48 hour) 
5.0 3.8 0.125 6.6 9.3 0.008
At 30 days
Death 3.6 1.7 0.002 9.6 6.4 0.005
Re-MI 1.3 2.1 0.18 2.0 2.8 0.16
Re-PCI 4.3 6.7 0.02 4.3 6.4 0.02
Re-CABG 2.3 3.1 0.25 3.6 4.6 0.23
Death and/
or re-MI 
4.6 3.7 0.25 20.3 8.7 0.05
MACE 11.8 3.7 0.10 20.3 8.7 0.41
At 1 year
Death 5.3 3.1 0.004 12.7 11.2 0.24
Re-MI 2.8 3.5 0.38 3.3 5.0 0.04
Re-PCI 12.7 13.6 0.55 10.1 12.2 0.12
Re-CABG 2.3 2.9 0.40 3.9 4.7 0.39
Death and/
or re-MI 
7.6 6.4 0.26 15.4 15.0 0.81
MACE 23.9 24.8 0.64 33 35.2 0.27
Values are %. Death is depicted as cumulative mortality.
MACE, combination of death, myocardial infarction, PCI, and/or CABG; MI, myocardial 
infarction.
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Table 4
Medication use at discharge by gender and age.
Women
<65 years 
n=708
Men
<65 years 
n=3006
p-value Women
≥65 years 
n=1047
Men
≥65 years 
n=1985
p-value
In the acute phase (since 2004)
Clopido-
grel
75 77 0.48 71 70 0.56
GP IIbIIIa 
inhibitor
27 28 0.69 25 25 0.79
At discharge
Aspirin 92 94 0.09 91 92 0.43
Beta-blocker 93 90 0.06 88 87 0.43
Statins 85 84 0.44 76 77 0.23
ACE 
inhibitor
55 57 0.36 54 59 0.01
Diuretics 8 8 0.87 21 16 <0.001
Insulin 5 3 0.02 6 4 <0.001
At 30 days
Aspirin 91 91 0.53 87 87 0.98
Beta-
blocker
93 90 0.08 89 88 0.29
Statins 88 89 0.51 81 82 0.36
ACE 
inhibitor
60 61 0.64 59 63 0.06
Diuretics 8 5 0.002 17 12 <0.001
Insulin 2 4 0.006 6 3 <0.001
Oral anti-
diabetics 
3 3 0.50 6 3 0.003
Values are %, ACE, angiotensin-converting enzyme; GP, glycoprotein IIbIIIa inhibitor.
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Women
<65 years 
n=708
Men
<65 years 
n=3006
p-value Women
≥65 years 
n=1047
Men
≥65 years 
n=1985
p-value
At 1 year
Aspirin 90 89 0.51 83 82 0.35
Beta-
blocker
83 79 0.05 81 81 0.70
Statins 91 90 0.37 83 83 0.70
ACE 
inhibitor
49 53 0.05 53 56 0.31
Diuretics 10 5 <0.001 19 13 <0.001
Insulin 4 2 0.014 6 3 0.004
Oral anti-
diabetics 
4 3 0.33 7 5 0.09
Values are %, ACE, angiotensin-converting enzyme; GP, glycoprotein IIbIIIa inhibitor.
Figure 1
Kaplan−Meier curves for gender and age groups in patients with ST-elevation 
myocardial infarction.
 
351
Figure 2
Multivariate analysis of 1-year mortality in women as compared to men, stratified 
to age. 
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Abstract
Background: Both acute hyperglycemia as diabetes results in an impaired 
prognosis in ST-elevation myocardial infarction (STEMI) patients. It is 
unknown whether there is a different prevalence of diabetes and acute 
hyperglycemia in men and women within age-groups.
Methods: Between 2004 and 2010, 4640 consecutive patients (28% 
women) with STEMI, were referred for primary PCI. Patients were 
stratified into two age groups, < 65 years (2447 patients) and ≥65 years 
(2193 patients). Separate analyses were performed in 3901 patients without 
diabetes. Diabetes was defined as known diabetes or HbA1c ≥6.5 mmol/l 
at admission.
Results: The prevalence of diabetes was comparable between women and 
men in the younger age group (14% vs 12%, p = 0.52), whereas in the 
older age group diabetes was more prevalent in women (25% vs 17% p 
< 0.001). In patients without diabetes, admission glucose was comparable 
between both genders in younger patients (8.1 ± 2.0 mmol/l vs 8.0 ± 2.2 
mmol/l p = 0.36), but in older patients admission glucose was higher in 
women than in men (8.7 ± 2.1 mmol/l vs 8.4 ± 2.1 mmol/l p = 0.028). After 
multivariable analyses, the occurrence of increased admission glucose was 
comparable between men and women in the younger age group (OR 1.1, 
95%CI 0.9-1.5), but increased in women in the older age group (OR 1.3, 
95% CI 1.1-1.7). Both diabetes and hyperglycemia were associated with a 
higher oneyear mortality in both men and women.
Conclusions: The differences between men and women in hyperglycemia 
and diabetes in patients with STEMI are age dependent and can only 
be observed in older patients. This may have implications for medical 
treatment and should be investigated further. 
Keywords
STEMI, Gender, Diabetes, Acute hyperglycemia
Background
Both hyperglycemia and diabetes are independent predictors of impaired 
prognosis after ST elevation myocardial infarction (STEMI) (1-4). 
Prevalences of both hyperglycemia and diabetes in STEMI are increased 
in women, which in part may explain their higher mortality rates (1,5,6). 
Moreover, diabetes has been associated with a higher cardiovascular 
mortality in women compared to men (7-9). In the general population 
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however, only in elderly people diabetes is more often present in women 
than in men (10). Until now, data with regard to the impact of age on the 
difference in prevalence of hyperglycemia and diabetes between men and 
women with STEMI are lacking. We investigated whether the differences 
in both hyperglycemia and diabetes are age-dependent within a large 
registry of patients with STEMI, treated with primary percutaneous 
coronary intervention (PCI).
Methods
We performed an observational study including all consecutive patients 
admitted with STEMI, referred for primary PCI to our hospital between 
2004 and 2010. Within these time frames, HbA1c and glucose were 
routinely measured on admission in all STEMI patients. Patients were 
diagnosed with STEMI if they had chest pain longer than 30 minutes 
and ECG changes with ST elevation greater than 2 mm in at least two 
precordial leads or greater than 1 mm in the limb leads. All patients were 
directly transported to the catheterization laboratory on arrival, and acute 
coronary angiography was performed with subsequent PCI when indicated 
as part of the routine treatment for all STEMI patients. The interventional 
strategy was at the operator’s discretion. All patients were pretreated with 
aspirin, heparin, and clopidogrel during transportation to the hospital 
according to protocol, or these drugs were administered at the emergency 
ward. Cardiac biomarkers were elevated in all patients. Diabetes was 
defined as known diabetes or a HbA1c ≥ 6.5 at admission. This HbA1c 
value was identified by the American Diabetes Association as diagnostic 
for diabetes mellitus (11). We performed additional analysis on a group 
without diabetes in order to concentrate on acute hyperglycemia due to 
stress. We conducted a multivariate analysis with gender as a predictor of 
a higher than median glucose levels. We corrected for confounders based 
on previously described variables in the literature (1,8). Therefore, the 
multivariate model consisted of gender, TIMI flow, Killip class and age.
Data collection
Patient characteristics were registered into a dedicated database. 
Thrombolysis in Myocardial Infarction (TIMI) (12) flow was scored 
according to the TIMI flow grading system before and after PCI. Follow-
up information was obtained with pre-defined time intervals of 30 days 
and one year using the outpatient files or by direct telephone interview 
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by independent research nurses not involved in patient treatment, 
The HbA1c levels were measured on the Primus Ultra 2 affinity 
chromatography-HPLC (Primus Diagnostics, Kansas City, MO) with a 
within run coefficient of variation of < 0.5%. The reference normal values 
in non diabetics were 4.0% to 6.5%. Glucose levels were measures with a 
Modular device (Roche Diagnostics). The reference values did not change 
during the study period and yearly numeric quality control data revealed 
that the coefficient of variation remained < 2%. 
Statistical analysis 
Statistical analysis was performed using SPSS version 17.0 (SPSS Inc, 
Chicago, IL). Continuous data were expressed as median and inter 
quartile range and categorical data as percentages. In order to examinate 
differences in women and men, we performed the Chi2 test for categorical 
variables and one-way Anova for continuous variables. The test for 
significance were two-sided with an α of < 0.5%. Multivariate analyses 
were performed using binary logistic regression. Predictors were identified 
using forward, stepwise logistic regression with the likelihood ratio test of 
all baseline variables with an α ≥ 0.1. The three most significant values and 
gender were entered into the final multivariate model. Kaplan Meier was 
performed with the log rank test for the p-values.
Results
A total of 4640 patients with STEMI were admitted between 2004 and 
2010. Mean age of the total population was 64 ± 13 years, including 1291 
women (28%). In the total population, the prevalence of hypertension was 
36%, smoking 41% and hypercholesterolemia 21%. A total of 464 (10%) 
patients had a previous myocardial infarction.
Effect of age
In older women, a higher killip class was observed compared to men. 
This difference was not present in the younger age group. The prevalence 
of known diabetes was 10% in men en 16% in women in the total study 
group (p < 0.001). Undetected diabetes was observed in 4% of men and in 
5% of women (p = 0.80), resulting in a significantly different prevalence of 
diabetes between both genders (p < 0.001). Diabetes was associated with 
an increased one-year mortality in both men (OR 1.9, 1.4-2.8 95% CI) and 
women (OR 2.1, 1.4-3.2 95% CI). In the older age group the prevalence 
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of diabetes was higher in women, while in the younger age group the 
prevalence was comparable (Table 1 and Figure 1). Hyperglycemia 
in patients without diabetes A total of 3901 patients had no diabetes, 
consisting of 1029 women (26%). Of the total group, 1761 patients (45%) 
were aged ≥65 years. Mean admission glucose was associated with both 
age and gender. Mean admission glucose was 8.2 ± 2.2 mmol/l in men and 
8.5 ± 2.1 in women (p = 0.001). The mean admission glucose was 8.3 ± 
2.6 mmol/l in younger patients and 8.9 ± 2.6 mmol/l in older patients (p < 
0.001). Baseline characteristics of the 3901 patients, stratified to age group 
and gender are summarized in Table 2. Besides differences in history of 
hypertension and smoking there were no significant differences in risk 
factors between men and women in the patient group below 65 years of 
age. In the older patient group however, men had more often a previous 
history of cardiovascular disease (prior PCI, CABG, myocardial infarction 
or stroke) while women were more often known with hypertension. 
Glucose level at admission was comparable between men and women in 
the younger age group, but higher in women at older age (Table 2) Also, 
the prevalence of admission glucose above the median was comparable 
within both genders at younger age in the multivariate model (OR 1.1, 
0.9-1.5 95% CI) while in the older age group, admission glucose above 
the median was more frequent in women. (OR 1.3, 1.1-1.7 95% CI) This 
age-related difference remained after multivariate analyses. In patients 
without diabetes, acute hyperglycemia was associated with an increased 
one-year mortality in both men (OR 2.2, 1.5-3.4 95% CI) and women 
(OR 2.9, 1.6- 5.4 95% CI). Mortality curves for patients without a history 
of diabetes are dichotomized into higher and lower than median glucose 
in women (8.1 mmol/l) and men (7.8 mmol/l) are depicted in Figure 2.
Discussion
In our present study of patients treated with primary PCI for STEMI the 
prevalence of diabetes was higher in older women compared to similarly 
aged men. In younger patients, however, we found no differences between 
men and women. Also, in patients without diabetes, a higher admission 
glucose could only be demonstrated in older women as compared to older 
men. Both diabetes and increased admission glucose in patients without 
diabetes, were associated with a higher one-year mortality in both women 
and men. Our study confirmed the increased prevalence of diabetes and 
acute hyperglycemia in women compared to men (5-7). A new finding 
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however in STEMI patients is that this association is age-dependent and 
only present in the older age-group. Diabetes (both known and unknown) 
confers to a greater risk for adverse cardiovascular events in women than 
in men (6,7). Therefore, the increased risk induced by diabetes in patients 
presenting with STEMI is predominantly observed in older women. In 
assessing the risk of adverse events in patients presenting with STEMI, 
both age and gender are important factors to consider. Importantly, the 
increased prevalence of diabetes in older women compared to older man 
is part of a different risk profile. Consistent with the literature, we found 
that men more frequently had ischemic heart disease in the medical 
history (6,7). Hypertension however was more common in both older and 
younger women, and this is interesting because hypertension has been 
associated with the development of diabetes (13-15). Hypertension may 
be an early sign of microvascular disease and increased risk of pre-diabetes 
and STEMI in (aging) women. The association between hypertension and 
diabetes is also important, since both risk factors induce microvascular 
and more diffuse coronary artery disease, which is more prevalent in older 
women (16-19). Our findings may have implications for medical treatment 
for patients with STEMI, since it has been shown that some antiplatelet 
drugs are more effective in patients with diabetes (20,21). Particularly 
since older women with abnormal glucose metabolism have a worse 
prognosis, optimal medical treatment is mandatory in this subgroup. It is 
important to discriminate diabetes from acute hyperglycemia at admission 
(1,22). High admission glucose in patients with diabetes is mainly due to 
glucose intolerance in the setting of diabetes. Whereas in patients without 
diabetes, hyperglycemia is probably associated with acute stress, induced 
by abnormal hemodynamics (1,23,24). There are several explanations for 
the increased prevalence of acute hyperglycemia in older women without 
diabetes. Firstly, although we excluded patients with increased HbA1c, 
several older women may have had abnormal chronic glucose metabolism. 
Therefore, women are more susceptible for hyperglycemia in response 
to a stressor, as compared to patients with completely normal glucose 
metabolism. Secondly, older women with STEMI may have had more 
acute stress as there is evidence that women more often present with 
cardiogenic shock compared to men (25). Also, in our study population 
older women had more often signs of heart failure on admission as 
compared to older men, whereas in the younger age group there was 
no difference in heart failure between men and women. However, after 
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adjustment for the observed differences in heart failure, we found that 
older women still had increased admission glucose levels. Finally, gender-
differences to stress in STEMI patients may be more present in elderly 
woman than in similarly aged men. Our study has several limitations. The 
number of patients in some subgroups were small, and the study was not 
powered to detect small differences between these subgroups. Also, the 
sample size was too small to demonstrate survival differences between men 
and women within the different age groups. Information regarding renal 
failure, liver failure, obesity, physical activity, inflammatory markers and 
socioeconomic status were lacking. Therefore, we were unable to adjust 
for these potential confounders. Finally, our data cannot be extrapolated 
to non-STEMI patients,non-cardiac patients admitted to intensive care 
wards, or unstable patients since our study included only STEMI patients 
and only 8% of these patients had a killip class higher than 1.
Conclusion
In STEMI, diabetes and hyperglycemia on admission is more prevalent 
in older women compared to similarly aged men. This association 
was not prevalent in younger patients. We observed an independent 
increased risk of acute hyperglycemia in older women without diabetes 
and therefore, older women may have an increased stress response. Both 
acute hyperglycemia and diabetes are associated with a worse prognosis 
in both women and men. More research is needed to elucidate these age-
dependent gender differences and to explore whether tailored treatment 
can improve prognosis.
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Table 1
Prevalence of diabetes in the total study population (n = 4640) according to gender 
and age group
Women 
<65
n=508
Men
<65
n=1939
p-value Women 
≥65
n=783
Men
≥65
n=1410
p-value
History of 
diabetes
54
(11%)
157
(8%)
0.15 155
(20%)
184
(13%)
<0.001
Newly detec-
ted diabetes *
13
(3%)
77
(4%)
0.16 35
(4%)
51
(4%)
0.17
Total without 
chronic diabetes
439
(86%)
1701
(88%)
0.52 590
(75%)
1171
(83%)
<0.001
Missing 2 4 3 4
* Patients without previously known diabetes and HbA1c ≥ 6.5% mmol/L
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Table 2
Baseline Characteristics according to gender and age groups <65 and ≥65 years 
in 3901 patients admitted for primary angioplasty for ST-segment elevation 
myocardial infarction (STEMI) without diabetes.
Women 
<65
N=439
Men
<65
N=1701
p-value Women 
≥65
N=590
Men 
≥65
N=1171
p-value
Age (year) 55
(48-60)
54
(49-59)
0.41 75
(70-81)
73
(69-78)
<0.001
History of, n (%)
MI 19
(4%)
113
(7%)
0.07 39
(7%)
176
(15%)
<0.001
CABG 5
(1%)
30
(2%)
0.36 13
(2%)
67
(6%)
0.001
PCI 21
(5%)
117
(7%)
0.11 36
(6%)
141
(12%)
<0.001
Stroke 5
(1%)
21
(1%)
0.87 17
(3%)
57
(5%)
0.05
Risk factors
History of 
hypertension
142
(32%)
431
(26%)
0.004 267
(45%)
432
(37%)
0.001
Positive family 
history
227
(53%)
841
(51%)
0.43 170
(30%)
310
(27%)
0.34
Current 
smoking
280
(65%)
963
(57%)
0.004 123
(21%)
263
(23%)
0.41
Hyper-
cholesterolemia
65(15%) 320
(19%)
0.06 99
(17%)
205
(18%)
0.66
Admission data
Glucose 
(mmol/l)
8.2 ± 2.2 8.0±2.2 0.36 8.7±2.1 8.4±2.1 0.03
Killip class = 1 412
(94%)
1619
(96%)
0.22 519
(88%)
1066
(91%)
0.05
TIMI-3 before 
PCI
105
(27%)
335
(22%)
0.06 116
(24%)
219
(22%)
0.36
Continuous variables are displayed as median and interquartile range.
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Figure 1
Prevalence diabetes in STEMI patients according to age and gender.
 
Figure 2 
Kaplan Meier mortality curves for patients without a history of diabetes, 
dichotomized into higher and lower than median glucose and stratified to gender 
(n = 3901).
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Abstract 
Objective: There is increasing evidence that reproductive factors are 
important in ischemic heart disease in women. We assessed the association 
between age at menarche and age of ST Elevation Myocardial Infarction 
(STEMI).
Methods: From 1998 until 2010 data from all women with STEMI 
were collected in Zwolle. Reproductive information was obtained in 688 
women with age at STEMI <75 years. Younger age of STEMI was defined 
as STEMI below 60 years. Age at menarche was categorized as ≤12 years, 
13 years, 14 years and ≥15 years. 
Results: STEMI at younger age was observed in 50%. In 20% of the 
patients, age at menarche was ≥15 years Younger age at menarche was 
associated with a higher prevalence of smoking, all other classical risk 
factors for cardiovascular disease were comparable between the 4 groups. 
After both unadjusted and multivariable analysis, women with a lower age 
at menarche had a higher probability of STEMI at younger age, with the 
adjusted OR 1.6 (95% CI 1.0-2.6) for age <12 years as compared to ≥15 
years. 
Conclusions: In a group with STEMI, women with early menarche have 
an independently increased risk of STEMI at younger age. More insights 
into the underlying mechanisms is warranted.
Keywords
Menarche, STEMI, age, women
 
Introduction
Ischemic heart disease (IHD) is an important cause of morbidity and 
mortality in women. In women, hormonal or reproductive factors during 
various stages of life can influence the risk of IHD (as1,2). For example, 
women with a late menopause have a lower cardiovascular risk compared 
to women with an early menopause (3-6). Whether other reproductive 
risk factors including age at menarche may be relevant in risk prediction 
of IHD is important to determine, since this can provide an additional 
opportunity for prevention. However, it is still unclear whether age of 
menarche is independently associated with cardiovascular mortality and 
morbidity. Several previous studies have shown conflicting results (7-
16). Most of these studies were performed in Asian women (7-10) or 
were performed with data more than 10 years ago (9-15). Furthermore, 
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most of the population-based studies did not have clinical information 
on IHD as the occurrence of myocardial infarction was diagnosed from 
death certificates, admission diagnosis and national or death registries (7-
9,13,17). Recently, a large cohort has been published revealing an u-shaped 
association for coronary heart disease deaths in early and late menarche 
(17). To assess the potential association between age at menarche and age 
at myocardial infarction, we performed a retrospective cohort study in 
women admitted with ST Elevation Myocardial Infarction (STEMI).
Materials and Methods
Population
From January 1998 to January 2010 individual data from all consecutive 
STEMI patients who were considered for primary Percutaneous Coronary 
Intervention (pPCI) at Isala Klinieken, Zwolle, were prospectively 
recorded in a dedicated database. Our institutional review board, METC 
(Medical Ethical Test Committee), was consulted and approval for this 
observational data collection was obtained. No questions were asked that 
need approval according to Dutch medical research involving human 
subjects act. 
All patients were informed at admittance that patient parameters were 
recorded for scientifical purposes. Information on demographic parameters 
and risk factors was entered into this database at the time of admission for 
STEMI. A positive family history was defined as a cardiovascular event in 
a relative ≤65 years. 
Questionnaires
A total of 1351 women aged <75 years presenting in our hospital between 
1998 and 2010 were included in the study and sent a questionnaire. The 
estimated response rate and recall bias in women >75 years at the time 
of STEMI would cause inaccurate data to be included and therefore, 
this was an exclusion criterion. The questionnaire was sent twice to non-
responders and all non-responders were contacted by telephone. A total 
of 771 women responded (57%) and of these patients, 688 patients (89%) 
provided information for age of menarche. We included all 688 patients 
in the statistical model for the association of age of STEMI and age of 
menarche. The questionnaire included questions on socioeconomic status, 
height (centimeters), weight (kilograms) and reproductive factors (age of 
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menarche, duration of oral contraceptive use, miscarriages, pregnancies, 
birth weight, gestational hypertension, preeclampsia, Hemolysis Elevates 
Liver enzymes and Low Platelets (HELLP) syndrome, gestational diabetes, 
hysterectomy, ovariectomy, age at menopause and perimenopausal 
symptoms). Miscarriage was defined as dead born foetus after pregnancy 
duration of <24 weeks and neonatal death was defined as death between 
birth and 28 days afterwards (18). The number of reproductive years was 
defined as age of natural menopause minus age at menarche. Hypertensive 
pregnancy disorders were defined as self-reported gestational hypertension 
or pre-eclampsia/HELLP in one or more pregnancies. A high level of 
education was defined as pre-university or university. BMI was calculated 
as weight in kilograms divided by square height at the time of STEMI. 
Late menarche was defined as ≥15 years and early menarche was defined 
as ≤14 years.
Outcome
Patients were diagnosed with STEMI according to the European Society 
of Cardiology guidelines if they had chest pain longer than 30 minutes 
and ECG changes with ST elevation greater than 2 mm in at least two 
precordial leads or greater than 1 mm in the limb leads. Cardiac biomarkers 
were elevated in all patients (19).
According to the protocol pPCI was performed using standard techniques, 
if the coronary anatomy was suitable for intervention. Success rate of the 
procedure was assessed with a classification for coronary flow according 
to Thrombolysis In Myocardial Infarction (TIMI) classification (20). 
Angiographic results were entered into the database at the time of 
angiogram. The mean age of first STEMI was 59 years and therefore, 
lower age of STEMI was defined as <60 years and higher age of STEMI 
was defined as ≥60 years.
Data analysis
Distributions of population characteristics for women with early and late 
menarche were expressed as means ± standard deviations for continuous 
data and as frequencies and percentages for categorical data, unless 
otherwise indicated. To compare characteristics between women with early 
and late menarche, we used chi-square tests with p-values for homogeneity 
for categorical variables and one-way ANOVA for continuous variables.
To evaluate differences between non-responders and responders, 
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admission data between these women were reported. To assess whether 
early menarche was independently associated with STEMI at younger age, 
we used a linear regression model with age at STEMI and age at menarche 
as continuous variables, adjusted for confounders. Furthermore, a logistic 
regression model was performed in which we categorized age of STEMI 
in 2 groups according to the mean age, <60 years and ≥60 years. Age at 
menarche was categorized in quartiles, ≤12 years, 13 years, 14 years and 
≥15 years, with ≥15 years as the reference group. The multivariate model 
also compromised smoking and BMI, since these are previously described 
in the literature as potential confounders for both early menarche and 
higher risk for IHD. Furthermore, we assessed which potential confounder 
deviated the beta-coefficient by more than 10%. This percentage was 
used, because it is most commonly used in the literature and this low value 
is known to best decide whether the confounder should be add into the 
model (21,22). All variables tested are displayed in table 1 and 2. Besides 
smoking and BMI, hypertension and number of miscarriages changed the 
coefficient by more than 0.1 and these variables were included into the 
final multivariate model. 
In 46% of patients, data on body mass index (BMI) were missing and 
we decided to impute these missing values by multiple imputation (23). 
Assuming these data were missing at random, a multiple missing value 
imputation procedure with m=5 was applied in which the values of the BMI, 
pre-eclampsia, HELLP, gestational hypertension gestational diabetes, 
education level, smoking, age, hypercholesterolemia, hypertension and 
diabetes were imputed in case they were missing. To study the “missing at 
random” assumption we compared the prevalence of all traditional- and 
female-specific risk factors between the persons with any missing values 
and without missing values. When comparing persons without any missing 
values (i.e., ‘complete cases’) to persons with one or more missing values, 
differences are found in particular in age at STEMI, hypertension, >10 
years of oral contraception and gestational hypertension. This indicates 
that missing values were not missing completely at random (MCAR) 
and using complete cases only would lead to biased estimates. Therefore 
in this situation with data being ‘missing at random (MAR), (multiple) 
imputation is the preferable approach, even though there is no method 
to test missingness not at random (MNAR) and therefore we cannot fully 
exclude this.
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Statistical analysis was performed using SPSS version 20.0 (SPSS Inc, 
Chicago, IL). Tests for significance were two-sided, with α=0.05.
Results
The mean age at the time of STEMI of the 663 non-responders was 
slightly higher than the 688 responders (62 vs. 60 years, p<0.005), 
diabetes and a history of myocardial infarction were more prevalent (14% 
vs. 11%, p=0.015 and 9% vs. 5%, p<0.001) and a positive family history 
was less often present (45% vs. 54%, p=0.007). Other general variables 
were comparable in both groups. Mean age at the time of STEMI was 
comparable between responders who contributed information about age 
of menarche or not (59 vs. 60, p=0.3). 
Of the 688 patients completed the question about age of menarche, 41% 
had anterior location of infarction and 51% had TIMI 0 flow (or no flow) at 
the initial coronary angiography. Compared to women with late STEMI, 
a higher percentage of women with early STEMI were smokers, with a 
positive family history, while they had less often hypertension (table 1).
Furthermore, women with late STEMI had a lower prevalence of 
preeclampsia and HELLP, were more often multigravida, with a higher 
birth weight of their first child and a lower prevalence of surgical 
menopause. 
Characteristics of early menarche
Women with an early menarche were more often smokers (p=0.02). Other 
classical cardiovascular risk factors as well as level of education were 
comparable between the 4 groups (table 2). Notably, women with early 
menarche did not have an earlier natural or surgical menopause compared 
to women with a late menarche. Duration of reproductive years was longer 
in women with early menarche (p<0.001). Miscarriages were more often 
observed in women with early menarche (p=0.02).
Association between age at menarche and age of STEMI
With linear regression, per year of increased age of menarche, the age at 
STEMI increased 0.79 years with a p-value of 0.001. Mean age of STEMI 
was different between the 4 menarche age groups. In bivariate logistic 
regression analysis, women with a lower age at menarche had a higher 
probability of having STEMI at younger age. Compared to women with 
highest menarcheal age ≥15 years, odds ratio (OR) and confidence intervals 
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(CI) were 1.8 (95%CI 1.2-2.8) for age-group <12 years, 1.2 (95%CI 0.8-
1.9) at 13 years, and 0.8 (95%CI 0.5-1.3) at 14 years. This association 
remained significant in the multivariate model with BMI. The OR and CI 
was 1.6 (95%CI 1.0-2.6) for age at menarche <12 years , 1.0 (95%CI 0.6-
1.6) at 13 years and 0.8 (95%CI 0.4-1.3) at 14 years, compared to women 
with menarcheal age ≥15 years (figure 1).
The multivariate model without BMI was comparable to the model with 
BMI. At <12 years the OR was 1.6 (95%CI 1.0-2.6), 1.0 (95%CI 0.6-1.6) 
at 13 years and 0.8 (95%CI 0.4-1.3) at 14 years, compared to women with 
menarcheal age ≥15 years. 
Discussion
This study demonstrates that early menarche is independently associated 
with a lower age at myocardial infarction. Several population based studies 
in the literature have suggested an increased premature risk of IHD in 
women with early menarche (7-11,17). This earlier presentation of IHD is 
presumably only partly associated with the higher prevalence of traditional 
cardiovascular risk factors in these women. In our study, only smoking was 
associated with earlier menarche. This underlines that hormonal-related 
factors, such as early menarche, may also play an important role in the 
development of IHD in women.
After menarche, endogenous oestrogen levels increase in women. 
Both observational and experimental studies have shown an overall 
cardioprotective role of endogenous oestrogens during the reproductive 
years of life (24,25). However, oestrogen exposure may also have negative 
effects on atherothrombotic risk. There are conflicting results in the 
literature whether a more adverse risk profile in patients corresponds with 
a higher number of reproductive years or cumulative years of exposure to 
endogenous sex hormones (1,3). Furthermore, early exposure to oestrogens 
instead of later vascular (protective) exposure may be disadvantageous 
for the onset of (cardio) vascular diseases (7-11). Possibly, the timing of 
oestrogen exposure in the reproductive years may be more important 
rather than the total number of years, as late menopause is protective for 
cardiovascular diseases and early menarche is not.
Confounders and intermediary factors influencing the age of menarche 
may also affect cardiovascular risk. There is evidence that in more than 
fifty percent of women the onset of menarche is caused by a combination 
of environmental and genetic factors (26-29) and up to date, more than 
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30 genetic loci have been identified to be related to age of menarche (30). 
In IHD, it is estimated that genetic predisposition accounts for 40 to 
60% of the disease risk (31,32). Although family history is an important 
cardiovascular risk factor in women with STEMI at younger age (33,34), 
we found no differences in family risk in women with early and late 
menarche.
In concordance with the literature, we found that early menarche is 
associated with a higher prevalence of smoking and this reinforces the 
need to discourage young women to start smoking (35). One possible 
explanation for this association is that girls with an early menarche are 
physically more mature than their counterparts with a later menarche 
and this may contribute to earlier engagement in tobacco use than their 
peers (36-38).  In line with this hypothesis, smoking is an intermediary 
factor in the association of age of menarche and age of STEMI. A recent 
large study, showing a u-shaped association between age of menarche 
and cardiovascular heart disease deaths irrespective of smoking, past 
smoking or non-smoking women, supporting the theory that smoking is 
an intermediate (17).
Another traditional risk factor and confounder for the relation with IHD 
possibly linked with age of menarche is BMI. An increased BMI is a risk 
factor for both early menarche as well as IHD (39-41). Although data 
in the literature are inconsistent about this correlation, the association 
between early menarche and STEMI at younger age did not change after 
correcting for BMI at STEMI in our present study.
We found a different prevalence of traditional risk factors between younger 
and older women with STEMI. In agreement with earlier observations, 
we observed a higher prevalence of hypertension and diabetes in older 
women with STEMI while smoking and a positive family history were 
more prevalent in younger women (42,43). This may facilitate a matched 
(secondary) prevention program since smoking, hypertension and diabetes 
are modifiable risk factors. Although we did not specifically investigate 
it, timing of menarche might be a valuable addition to long term 
cardiovascular risk prediction in women. Individual risk algorithms may 
be improved if reproductive risk factors are incorporated (44). Currently, 
age of menarche seems to be a relatively more accurate risk factor than 
age at menopause, since many women use oral contraceptives during 
menopause transition, hiding their true age of menopause.(45) More 
studies are needed to further investigate whether age of menarche may be 
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a valuable addition in risk algorithms.
Worldwide, a decline in age of menarche is observed presumably due to 
several factors as increased obesity or exposure to environmental toxicants 
(46). Combined with an increase in adverse life-style factors in younger 
generations, this may be a signal for a higher cardiovascular disease risk 
profile in future generations. 
Limitations:
An important limitation of our study was the low response-rate at the 
questionnaire (57% responders), and the fact that several baseline variables 
(as age at STEMI, diabetes) were different between responders and non-
responders. Furthermore, the non-survivors only were present in the non-
responder group. This may influence both internal and external validity 
of the study.
We do not have information about hormonal use during menopausal 
transition, birth weight, detailed subsequent menstrual cycles, 
hypoandrogenic state or PCOS, although it is likely that hormonal use 
during menopause is 5% (47). Future studies should include these data 
and focus more on women specific risk factors.
Although age at menarche is an occurrence that is mostly well 
remembered by women, a modest recall bias may be present (48). This 
is likely independent of age at STEMI and may therefore lead to an 
underestimation of the association between menarcheal age and outcome 
in this study. Self reported pre-eclampsia could not be validated with 
medical records and may be moderately valid, although misclassification 
may be not different between higher and lower age of STEMI and not 
influence the results (49). 
Although general variables are prospectively entered into this database and 
most variables therefore had a relatively low percentage of missing data 
(<2%) we had 46% missing data on BMI at admission. Therefore, we used 
multiple imputation of the missing BMI variables on order to enhance 
statistical power in the multivariate analysis. We also have no detailed 
information about various ethnic groups, although it is ascertained that 
this STEMI population is mainly of white origin, since our hospital is 
located in a rural area in the Netherlands. 
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Conclusions
Early menarche is independently associated with STEMI at a younger age 
and this is not mediated through classical cardiovascular risk factors. A 
better understanding of the underlying mechanisms is needed.
 
Table 1
Traditional ischemic heart disease risk factors and reproductive factors in 688 
women with STEMI < 75 years, stratified to age at STEMI.
 
Menarche
≤ 12 years
n=254
Menarche
= 13 years
n=166
Menarche
= 14 years
n=131
Menarche
≥ 15 years
n=137
p-value
Age at STEMI 
(years) 
57±10 59±10 61±10 59±10 0.01
BMI (kg/cm2) 27±5 26±4 27±5 26±4 0.08
Previous MI 4% 4% 2% 8% 0.08
Previous CABG 1% 2% 1% 3% 0.32
Previous PCI 4% 2% 2% 4% 0.51
Previous Stroke 2% 2% 1% 2% 0.71
Diabetes 12% 9% 10% 14% 0.53
Hypertension 39% 31% 32% 36% 0.12
Hyper-
cholesterolemia
18% 22% 22% 29% 0.13
Positive family 
history
53% 52% 54% 55% 0.95
Smoking (ever) 60% 54% 50% 45% 0.02
High level of 
education
11% 10% 9% 12% 0.82
≥ 10 years of oral 
contraception 
48% 45% 51% 42% 0.66
Intra uterine 
device (ever)
21% 18% 15% 20% 0.64
One or more 
pregnancies
93% 90% 92% 93% 0.48
Multigravity (≥ 4) 19% 24% 18% 22% 0.58
Birth weight first 
child (gram)
3156±804 3259±800 3277±865 3290±942 0.51
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Menarche
≤ 12 years
n=254
Menarche
= 13 years
n=166
Menarche
= 14 years
n=131
Menarche
≥ 15 years
n=137
p-value
Gestational 
hypertension
23% 24% 27% 19% 0.65
Pre-eclampsia/
HELLP
5% 4% 7% 3% 0.5
Gestational 
diabetes
4% 2% 6% 8% 0.07
Miscarriage 32% 26% 16% 28% 0.02
Neonatal death 6% 2% 2% 7% 0.1
Surgical 
menopause < 50 
years
16% 8% 14% 13% 0.25
Age at 
menopause 
(years) 
46±5 47±5 47±5 46±6 0.71
Number of 
reproductive 
years
35±7 35±5 33±6 32±6 <0.001
Perimenopausal 
complains
98% 96% 97% 98% 0.76
HELLP = Hemolysis Elevates Liver enzymes and Low Platelets.
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Table 2
General characteristics of women with a STEMI < 75 years, stratified by age of 
menarche.
Variable (sample size) Women 
<60 year
n=350
Women
≥ 60 year 
n=338
p-value
Age at STEMI (years) (n=688) 50±6 67±4 <0.001
BMI (kg/cm2) (n=370) 27±5 26±4 0.56
Previous MI (n=684) 5% 4% 0.51
Previous CABG (n=684) 0% 3% 0.009
Previous PCI (n=684) 10% 11% 0.76
Previous Stroke (n=683) 2% 2% 0.95
Diabetes (n=681) 8% 14% 0.009
Hypertension (n=674) 31% 42% 0.002
Hypercholesterolemia (n=659) 20% 25% 0.13
Positive family history (n=671) 63% 43% <0.001
Smoking, ever (n=686) 71% 35% <0.001
High level of education (n=652) 11% 10% 0.45
≥ 10 years oral contraception (n=475) 56% 32% <0.001
Intra uterine device, ever (n=686) 28% 10% <0.001
One or more pregnancies (n=652) 89% 94% 0.07
Multigravity, > 4 births (n=575) 12% 25% <0.001
Birth weight first child, gram (n=686) 3152±845 3385±951 <0.001
Gestational hypertension (n=686) 23% 23% 0.91
Pre-eclampsia/HELLP (n=686) 7% 3% 0.03
Gestational diabetes (n=686) 4% 2% 0.14
Miscarriage (n=585) 25% 20% 0.10
Neonatal death (n=597) 5% 6% 0.74
Surgical menopause < 50 years (n=680) 17% 10% 0.023
Age at menopause, years (n=540) 47±6 47±6 0.91
Number of reproductive years (n=540) 34±6 34±6 0.25
Perimenopausal complains (n=597) 92% 92% 0.89
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Figure 1
Multivariate logistic regression of early menarche as a risk factor for early 
STEMI in a population of STEMI patients <75 years. 
Corrected for: smoking, BMI, hypertension and number of miscarriages.
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Spontaneous coronary artery dissection (SCAD) is a rare and poorly 
understood cause of myocardial infarction and sudden cardiac death (1–5). 
In ST elevation myocardial infarction (STEMI), SCAD is more common 
in young women than men (2). There are currently no guidelines for 
acute and chronic management of these patients. According to previous 
reports, about half of SCAD patients with STEMI are treated with 
percutaneous coronary intervention (PCI), but it is debatable whether this 
treatment is beneficial (2,4,5). Moreover, it is unclear yet which secondary 
prevention strategy after SCAD is effective. In order to investigate the 
initial treatment assignment and angiographic success in a larger cohort, 
we evaluated all women <50 years with STEMI admitted in our hospital 
between January 1998 and December 2010. During the study period, 263 
women <50 years with STEMI were admitted. All angiographies were 
retrospectively reviewed by two experienced interventional cardiologists, 
without knowledge of the general characteristics. The presence of SCAD 
was suspected if there was an angiographic characteristic finding suggesting 
the presence of coronary artery dissection (3,6,7). A definite diagnosis of 
SCAD was given if there was an agreement between both reviewers.
SCAD was observed in 26 patients (10%). Differences in the general 
characteristics between women with and without SCAD are presented 
in Table 1. Though not statistically different, hypercholesterolemia 
was less present in women with SCAD (20% vs. 8%, p = 0.12). Other 
general variables, including duration of ischemic time were not different 
between women with and without SCAD. In both groups the prevalence 
of smoking was high (80% and 73%). TIMI 3 flow was comparable 
between women with and without SCAD at the start of the angiography 
(30% vs. 48%, p = 0.62). However, in women treated conservatively or 
with PCI, at the end of angiography, TIMI 3 flow was less prevalent 
in women with SCAD than in women without SCAD (73% vs. 95%, 
p < 0.001). Especially in women treated with PCI (n = 236), TIMI 3 flow 
was less often reached in patients with SCAD than in women without 
SCAD (61% vs 96%, p < 0.001). A worse prognosis should be expected in 
patients with SCAD since an impaired coronary flow is established as an 
important endpoint in STEMI patients, associated with a higher mortality 
(8). There were important differences in treatment assignment between 
patients with and without SCAD (Fig. 1). Patients with SCAD were 
significantly more often treated conservatively compared to non-SCAD 
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patients. Conservatively treated women with SCAD more often had TIMI 
3 flow at the start of the procedure compared to women with SCAD treated 
with PCI (88% vs 29%, p = 0.007). Furthermore, conservatively treated 
SCAD patients had a smaller enzymatic infarction compared to SCAD 
patients treated invasively or with PCI. It is therefore likely that these 
conservatively treated patients were at lower risk for adverse events or 
impaired coronary flow at the end of the procedure. Unfortunately, OCT 
or IVUS was not routinely performed in our patients to provide additional 
information on the length and type of dissection (9). Concluding, SCAD 
can be observed in 10% of women <50 years presenting with STEMI. 
Women with SCAD were treated more often conservatively. PCI in 
women with SCAD was more often unsuccessful. More research should 
be encouraged to clarify mechanisms and optimal treatment.
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Table 1
Patient characteristics of 263 women <50 years with ST Elevation Myocardial 
Infarction. 
237 women 
without 
SCAD 
26 women 
with
SCAD
p-value
Age (years) 
mean ± SD
44 ± 5 45 ± 4 0.15
BMI (kg/cm2) 
mean ± SD
26 ± 4 26 ± 5 0.96
Previous MI 8 (3%) 0 (0%) 0.34
Previous CABG 0 (0%) 0 (0%) -
Previous PCI 9 (4%) 0 (0%) 0.31
Previous Stroke 1 (0%) 0 (0%) 0.74
History of diabetes 14 (6%) 0 (0%) 0.20
History of hypertension 50 (22%) 8 (31%) 0.29
Positive family history 142 (62%) 13 (52%) 0.36
Current smoking 187 (80%) 19 (73%) 0.42
Hypercholesterolemia 44 (20%) 2 (8%) 0.14
Killip class = 1 on admission 221(95%) 25(96%) 0.77
Total ischemic time (min) 
mean ± SD
260 ± 168 287 ±239 0.66
SD: standard deviation
BMI: Body Mass Index
MI: Myocardial Infarction
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Figure 1
Treatment assignment in women <50 years referred for ST elevation myocardial 
infarction.
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Initial clinical presentation of tako-tsubo cardiomyopathy (TTC) often 
mimics ST-elevation Myocardial Infarction (STEMI), including acute 
chest pain, ST-segment elevation and raised cardiac biomarkers(1). TTC 
mostly occurs in post-menopausal women, and has been associated with 
acute stress, smoking, alcohol abuse and hypercholesterolemia(2). It is yet 
unclear why TTC is more often observed in women and whether increasing 
age is a predictor of TTC in both men and women. Possibly, cardiovascular 
risk factors for STEMI may also be associated with an increased risk of 
TTC(3). Since men and women with STEMI have a different, age-related 
risk profile, there may also be an age-related difference between genders 
in TTC(4). Although case series are available regarding predictors of 
TTC, only few studies focus on gender differences(5). Furthermore, no 
studies report a control group of STEMI patients, which is important to 
differentiate ischemic cause of STEMI and TTC in order to investigate 
the pathophysiological mechanisms(1,5). We investigated whether there 
is an independent age-related difference in TTC in both men and women 
who present with STEMI. We included all 10166 STEMI patients 
admitted between January 1998 and December 2013. Patients were 
diagnosed with TTC according to Mayo Clinics diagnostic criteria(1). All 
patients with TTC had transient hypokinesis, dyskinesis or akinesis of the 
left ventricular mid segments with or without apical involvement. Patients 
with myocarditis or pheochomocytoma were excluded. 
Furthermore, organic stenosis or spasm of a coronary artery perfusing 
the territory of hypo- or akinesis of the myocardium is an exclusion 
criteria for TTC. Therefore, we examined all patients not treated with 
pPCI or coronary artery bypass grafting(1). Patients with a myocarditis 
or pheochromocytoma were excluded. We retrospectively examined all 
angiograms and echocardiograms of the remaining 685 STEMI patients 
to identify whether TTC was present. Chi2 test was used for categorical 
variables and one-way ANOVA for continuous variables. To analyse 
whether there was an independent association in men and women with 
and without TTC according to age, binary logistic multivariate regression 
was performed. The multivariate model consisted of all baseline variables 
between men and women with α <0.1 and all baseline variables in patients 
with and without TTC with α <0.1. The final multivariate model consisted 
of age, previous myocardial infarction, previous PCI, previous CABG, 
diabetes, hypertension and current smoking. 
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TTC was observed in 43 patients (0.4% of the total population, 5.6% of the 
patients treated conservatively). Differences in the general characteristics 
and hemodynamic parameters between women and men with and without 
TTC are presented in the table. In both men and women, patients with 
TTC were less often current smokers. Men with TTC were significantly 
younger than men without TTC (figure). However, women with and 
without TTC had comparable age. Women with TTC, were older than 
men with TTC (70 vs. 50 years, p<0.001). Women without TTC were 
older than men without TTC (67 vs. 62 years, p <0.001) and except one 
women of 40 years, all women were above 50 years of age at the time of 
TTC.
Although in men with STEMI the observed amount of TTC is low (0.12%), 
TTC is more often observed in younger men. In women with STEMI, the 
observed amount of TTC is higher (1.3%), but not associated with age. 
This novel finding may give new insights in the aetiology of TTC. 
The main hypothesis on the pathophysiological mechanism of TTC is the 
combination of an increased sympathetic stress reaction with excess release 
of catecholamines, followed by an abnormal response to this catecholamine 
release(6). An important explanation for the age related difference in 
prevalence of TTC in men, but not in women, may be differences in stress 
hormones that are also related to estrogen status during life. In animal 
models, an age related decrease in noradrenergic nerve fibres and increase 
of catecholamine levels with ageing is observed(7). This means that 
theoretically both younger men and women may have an increased risk 
of a TTC. The elevated levels of premenopausal estrogen however may 
compensate for high levels of catecholamine release in younger women, 
but not in men. Women have an increased response to adrenergic stress 
after menopause, which may add to their increased risk of TTC(8,9). 
Low estrogen status in the postmenopausal years, leads to an impairment 
in vasodilating and vasoconstrictive reactivity, resulting in an increased 
responsiveness to sympathetic activity (10). In postmenopausal women, the 
epicardium is relatively unprotected against an adrenergic storm, resulting 
in a predisposition for TTC when a severe stress event occurs. Another 
explanation of the higher prevalence of TTC in older women, but not in 
older men may be that the acute excess of catecholamine in TTC leads 
to an impaired vascular reactivity through endothelial dysfunction(11), 
especially in the microcirculation. As microvascular coronary dysfunction 
is often present in elderly (hypertensive) postmenopausal women, they 
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may be at increased risk to develop TTC (12). Since similarly aged 
elderly men have a lower prevalence of hypertension and microvascular 
dysfunction, (13) this may also explain the lower incidence of TTC 
compared to women. Finally, another reason for a higher prevalence of 
TTC in men at younger age, may be more misdiagnosis of TTC in older 
men. As significant coronary artery disease is often present in ageing men, 
it is more likely that an occurring TTC remains unrecognized, and is 
assigned to a coronary lesion that is considered as the  culprit lesion. For 
the same reason, TTC may be more often misdiagnosed in men as in 
women, since there is a higher prevalence of obstructive coronary artery 
disease in men compared to women(4). 
Concluding, in patients presenting with STEMI, we observed that 
younger men have an increased risk of TTC compared to older men. 
The age of women with TTC was comparable to women without TTC 
and women with TTC were older than men with TTC. This suggests a 
different mechanism of TTC patients between men and women with a 
possibly hormonal protection in younger women.  
Figure
Age at admittance with women and men presenting with a ST-Elevation 
Myocardial Infarction. 
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Table
Women and men presenting with STEMI stratified into with and without tako 
tsubo cardiomyopathy
Women
with
TTC 
(n=34)
Women
without
TTC 
(n=2671)
p-value Men
with
TTC 
(n=9)
Men
without
TTC 
(n=7381)
p-value
Risk Factors, n(%)
History of MI 2
(6%)
199
(7%)
0.73 1
(11%)
850
(12%)
0.97
History of 
CABG
1
(4%)
69
(3%)
0.41 0(0%) 269
(4%)
1
History of PCI 0
(0%)
156
(6%)
0.26 1
(11%)
695
(9%)
0.86
History of 
Stroke
2
(6%)
90
(3%)
0.32 0
(0%)
228
(3%)
1
History of 
hypertension
12
(35%)
1186
(45%)
0.11 0
(0%)
2327
(32%)
0.065
History of DM 3
(9%)
432
(16%)
0.25 0
(0%)
726
(10%)
1
Hyperlipidemia 6
(18%)
551
(21%)
0.60 1
(11%)
1606
(23%)
0.41
Pos Family 7
(21%)
989
(38%)
0.05 3
(33%)
2841
(40%)
0.71
Current 
smoking
5(15%) 1031
(39%)
0.004 1
(11%)
3301
(45%)
0.05
Admission data
Killip class > 1 1
(4%)
242
(11%)
0.33 0
(0%)
465
(7%)
1
Systolic blood 
pressure 
(mmHg)
136±29 134±29 0.38 123±31 132±26 0.37
Diastolic 
blood pressure 
(mmHg)
82±14 79±20 0.45 75±19 80±17 0.51
Heart rate 
(per minute)
84±15 78±19 0.042 73±16 76±19 0.70
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Abstract
Background: Tako Tsubo cardiomyopathy(TTC) often presents with 
the clinical signs of ST-elevation myocardial infarction(STEMI). The 
increase in scientific publications addressing this relatively rare condition 
may result in higher awareness and diagnosis of TTC. 
Aim: To assess the observed prevalence/year of TTC in a large registry of 
patients with STEMI, during a 12 year inclusion period. 
Method: All patients presenting with STEMI at a large regional cardiology 
clinic were entered into a database(N=8413, mean age=63±13 years). TTC 
was diagnosed in 42 patients(0.5%). Years of evaluation were defined as 
“early years”(January 2002 until December 2007; N=4350) and “later 
years”(January 2008 until December 2013). Multivariable analyses were 
performed to adjust for differences in demographic and clinical variables.
Results: In later years, the age of STEMI patients was slightly higher(64±13 
vs. 63±13 years,p<0.001), with more patients with clinical symptoms of 
shock(10% vs. 7%,p<0.001) or a history of PCI or hypertension(10% 
vs. 8%,p=0.001 and 37% vs. 34%,p<0.001). Smoking and a positive 
family history were less often observed during later years(39% vs. 
46%,p<0.001 and 37% vs. 42% p<0.001). Patients with TTC were more 
often female(81% vs 27%, p=0.001). TTC was more often diagnosed in 
later years(0.7% vs. 0.3%, OR2.4, 95% CI 1.2-4.6,p=0.009). The higher 
prevalence of TTC in recent years remained significant after adjustment 
for differences in patient characteristics (OR2.1, 95% CI 1.1-4.3). 
Conclusion: TTC is currently more often diagnosed in patients with 
STEMI compared to earlier years. This is probably due to the increased 
scientific and clinical awareness among doctors, but the prevalence is still 
low. 
Introduction
Tako Tsubo cardiomyopathy (TTC) is characterized by transient wall 
motion abnormalities mimicking ST-elevation myocardial infarction 
(STEMI). It was first described in 1991 in Japan (1). At that time, TTC 
was completely unrecognized in Europe and North America and it was 
thought only to occur in Asia, where the first cohorts were published 
approximately 10 years later (2,3). The first observation of TTC in 
Caucasian patients was published in 2003 (4). Since then, awareness of 
TTC in Europe and North America among cardiologists has increased, 
with more patients initial presenting as STEMI being diagnosed as TTC. 
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However, it is also likely that a distinctly different population of patients 
are referred for STEMI over time due to improved therapy, logistics and 
modifications in referral (5,6). This may contribute to a shift in observed 
numbers of TTC. For instance, as currently more elderly women with 
STEMI are referred for immediate PCI, the number of observed TTC 
may have increased, since it is more prevalent in post-menopausal women 
(7,8). To assess alterations of the observed prevalence of TTC in patients 
with STEMI, adjustments should be made for these potential confounding 
factors (3,9,10). In the current study, we investigated whether the observed 
number of patients with TTC changed over a 12 years time period and if 
this is related with alterations in patient characteristics. 
Methods
From January 2002 to December 2013 individual data from all STEMI 
patients who were considered for primary PCI (Percutaneous Coronary 
Intervention) and who underwent early coronary angiography at our 
centre, were prospectively recorded in a dedicated database. Early years 
were defined as January 2002 until December 2007 and later years were 
defined as January 2008 until December 2013. Patients were diagnosed with 
STEMI if they had chest pain longer than 30 minutes and ECG changes 
with ST elevation greater than 2 mm in at least two precordial leads or 
greater than 1 mm in the limb leads. Cardiac biomarkers were elevated in 
all patients. Information on demographic variables was directly registered 
at first contact with the patient, including age, sex, medical history, family 
history and traditional cardiovascular risk factors. In patients in whom 
echocardiography during admittance or after one month for assessing the 
left ventricle function was performed, the echocardiography was reviewed 
by an expert cardiologist or a resident cardiology supervised by an expert 
cardiologist. In order to investigate the number of publications concerning 
TTC, we sought in the PubMed database with the following search 
strategy per year: (“2002/01/01”[Date-Publication] : “2002/12/31”[Date 
- Publication]) AND ((tako AND tsubo) OR takotsubo). Although TTC 
is sometimes mentioned as ‘ampulla cardiomyopathy’, ‘apical ballooning 
syndrome’, ‘broken heart’ or ‘stress induced cardiomyopathy’ in the 
literature, almost all articles were still revealed with the search strategy 
because Takotsubo or Tako Tsubo was mentioned in the article (11-13). 
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TTC definition
ECG changes (either ST-segment elevation and/or T wave inversion) are 
major diagnostic criteria for TTC. Since all patients in our database had 
ST-elevation, this criterium was fulfilled for all patients. The presence of 
an epicardial stenosis or spasm of a coronary artery perfusing the territory 
of hypo- or akinesia of the myocardium are exclusion criteria for TTC (7, 
14). Patients with TTC had transient hypokinesia, dyskinesia or akinesia 
of the left ventricular mid segments with or without apical involvement 
according to the Mayo Clinics diagnostic criteria (10). 
Statistical analysis
Statistical analysis was performed using SPSS version 20 (SPSS Inc, 
Chicago, IL). Continuous data were expressed as mean and standard 
deviation and categorical data as percentages. Tests for significance were 
two-sided and values with an α of 0.05 were considered significant. In order 
to analyse whether an independent association was present of the frequency 
of observed TTC patients over time and the number of publications, we 
used binary logistic regression comparing early years to later years. The 
multivariate model consisted of all baseline variables with a p ≤0.1 (gender, 
age, previous PCI, hypertension, smoking, hypercholesterolemia, positive 
family history and Killip class ≥ 2).
Results
In total, 8413 patients with a STEMI were referred to our centre during 
a 12 year time period. The mean age was 63 ± 13 years. During the 
study period, 685 (8%) patients had no identifiable stenosis or spasm of a 
coronary artery at angiography. These patients may have had a diagnosis 
of TTC according to the Mayo Clinics diagnostic criteria (10). All patients 
had complete resolution of the myocardial segments on echocardiography 
or angiography within a month. Two patients with myocarditis were 
excluded and there were no patients with a pheochomocytoma. Of these 
685 patients, 1 month follow-up data on left ventricular function were 
missing in 2 patients from 2002, therefore these were excluded from 
further analysis. In total, 42 patients (0.5%) were diagnosed with TTC 
according to the criteria as described in the methods. 
The 643 patients who were treated conservatively and did not have 
TTC, were older than invasively treated patients (65±16 vs. 63±12 years, 
p=0.002). They were also more often female (31% vs. 27%, p=0.01), more 
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often had a history of myocardial infarction (15% vs. 10%, p<0.001), a 
history of CABG (9% vs. 3%, P<0.001), a history of PCI (12% vs. 9%, 
p0.02), a history of CVA (6% vs. 3%, p<0.001).
hypertension (41% vs. 36%, p=0.007) and diabetes (14% vs. 11%, p=0.03). 
Patients treated conservatively less often had a positive family history (31% 
vs. 40%, p<0.001) and were less often smokers (30% vs. 44%, p<0.001).
Trends over the years in patients referred for STEMI
Compared to earlier years, patients referred for STEMI during 2008-2013 
were older and  more often had a history of previous PCI, hypertension, 
and a higher Killip class at admission. Current smoking and a positive 
family history were less often present in later years. Furthermore, the 
duration of hospital stay was slightly longer in later years. The other 
clinical characteristics including gender did not change over time (table 
1). 
Difference in patients with and without Tako Tsubo
Patients with TTC were more often older, female, less often current 
smokers and had a higher heart rate at admission compared to usual STEMI 
patients (table 2). All other cardiovascular risk factors and hemodynamic 
parameters were comparable between patients with and without TTC.
Trends over the years in prevalence of TTC
The annual observed prevalence of TTC in patients with STEMI ranged 
from 0% in 2002 to 1.05% in 2009 and significantly increased over time 
(Figure 1). Compared to the number of patients with TTC in the early 
years, TTC was more often observed in the later years (OR 2.4, 95% CI 
1.2-4.6). In the multivariate model, this difference remained significant 
(OR 2.1, 95% CI 1.1-4.3). 
The literature search showed that in the early years, Tako Tsubo was less 
often mentioned in the literature compared to later years (figure 2).
Discussion
In this large cohort of patients with STEMI, we found a significant increase 
in the number of patients observed with TTC over time, independent 
from patient characteristics. However, the prevalence of TTC among 
STEMI patients is still low. 
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The prevalence of TTC in the literature ranges from 0.02% in general 
population to 1-2% in populations with acute coronary syndromes (14,7). 
However, these prevalences cannot be compared with our study because 
we present a cohort of patients with STEMI. To our knowledge, this is the 
first STEMI population being studied for TTC. 
The increased number of observed TTC-patients over the years may have 
different explanations. Firstly, since patients with STEMI are currently 
older and TTC is associated with increasing age, TTC may be more often 
diagnosed (15-17). However, this cannot be the entire explanation for the 
increased frequency of observed TTC patients, because after correcting 
for age in the multivariate model there was still a relationship between later 
years and an increase of observed TTC in our study. Another explanation 
for an increase of TTC may be changed risk profiles of admitted STEMI 
patients over the years, what was also observed in other studies (18,19). 
These changes in risk factors only partly explain the difference of observed 
frequency of TTC patients in our study, since after multivariable analyses 
the frequency of TTC was still higher in the recent years. A third, and 
probably most important reason for the increased frequency of TTC 
may be due to improved network and facilities in the treatment of acute 
STEMI patients. In fact, almost all STEMI patients are currently referred 
to a tertiary centre with primary PCI facilities. Furthermore, improved 
recognition of TTC may also play an important role, which may be 
related to a higher awareness of cardiologists and other medical personnel 
due to an increasing number of scientific studies on TTC in the literature 
and communication at conferences (figure 2). Large systemic registries or 
multicentre trials (20-22) do not only increase awareness, they also result 
in a better understanding of the demographics and ultimately also the 
(medical) therapy of TTC. Furthermore, case reports concerning a new 
clinical presentation of TTC are more often published (23,24).
In our study, left ventricle (LV) function was assessed with an echo or 
LV angiogram primarily in the acute situation after STEMI. Therefore, 
we used only the LV function assessment in the acute setting. However, 
standard evaluation of the LV function both in the acute moment and 
after one month can avoid misdiagnosis of TTC. The ESC guidelines also 
recommend evaluation of resting LV function both in the acute moment 
and after more than two weeks after STEMI (25). If the outpatient LV 
assessment is performed after 4 weeks from STEMI, most TTC patients 
can be diagnosed with more certainty, because LV function due to TTC 
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should be normalised within 4 weeks according to the TTC definition 
(26). 
Although we evaluated every STEMI patient without coronary intervention 
for possible TTC, only 0.5 % of all patients with STEMI admitted in our 
hospital were diagnosed as TTC. Our observed prevalence of TTC is 
lower than estimates in the literature and therefore it is likely that we 
may have underdiagnosed TTC in our database (9,27,28). Particularly in 
patient groups with a high prevalence of coronary artery disease, TTC 
may be underdiagnosed. As both coronary artery disease and TTC might 
be present in these patients and TTC can only be diagnosed in absence of 
a significant coronary artery stenosis, a TTC may not be recognized (27).
Discriminating TTC with heart failure from STEMI with heart failure, is 
of importance because it may have important implications for treatment. 
Firstly, although it has not been properly studied, medical treatment for 
systolic heart failure can be considered in TTC patients in order to relieve 
acute symptoms (e.g. oedema) (29). Three important drugs to administer 
to these patients are mineralocorticoid receptor antagonists, beta blockers 
and angiotensin-converting enzyme (ACE)- inhibitors (or angiotensin 
receptor blocker) (30). When LV function normalises in TTC patients 
after one month, it could be considered to stop the ACE-inhibitor and the 
mineralocorticoid –receptor antagonist to avoid adverse events associated 
with these drugs (31). Although evidence is limited, the continuation of 
beta blockers can be considered in patients with TTC, because of the 
theory that TTC is caused by sympathetic hyperactivity (32).
Secondly, temporal aggressive heart failure treatment as LV assist devices 
may be considered in TTC patients if needed, even if the patient is not a 
heart transplant candidate (33). Misdiagnosing a TTC patient for a patient 
with a type 1 myocardial infarction, may result in unnecessary long-term 
treatment with dual anti platelet therapy. Without a plaque rupture, only 
long term prescription of acetylsalicylic acid is indicated and without 
coronary artery disease no anti platelet therapy at all should be given 
in TTC patients. This will potentially diminish bleeding complications 
(34). Finally, since TTC in most patients has a good prognosis, especially 
after 4 weeks, when LV function normalises, patients may receive more 
adequate information about their prognosis.
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There are several opportunities to improve diagnosing TTC. First of 
all, increased awareness in doctors and (possibly) patients is necessary. 
Moreover, a history of emotional trigger(s) must prompt the doctor to put 
TTC in the differential diagnosis. This is especially so in elderly women 
presenting with STEMI, because the prevalence of TTC is highest in this 
patient group (10). The evaluation of possibly emotional triggers should 
be routinely done in every patient with STEMI. Furthermore, when a 
coronary stenosis, but not a coronary occlusion is observed with invasive 
angiography, fractional flow reserve could be considered to evaluate 
whether the stenosis is hemodynamically significant in a later phase. 
If no epicardial coronary stenosis is found as the cause for the STEMI 
at coronary angiography, apart from routine echocardiography, a LV 
angiography can visualize an apical ballooning pattern of the LV.
Study limitations
This study was performed retrospectively in the beginning years 
not all patients received sequential imaging of the left ventricular 
function. Therefore, it is likely that especially patients with TTC were 
underdiagnosed.  
Conclusions
We observed an increased frequency of observed TTC over the years. 
Since this difference remained irrespective of classical cardiovascular risk 
factors, and since TTC received more attention in the literature in the 
course of this study, it is likely that increased awareness contributed to this 
increase. National registries for patients with TTC may further increase 
awareness and stimulate scientific research about aetiology and (medical) 
treatment of TTC. 
Conflict of interest: none declared
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Table 1
Clinical characteristics of patients referred for STEMI in early (2002-2008) and 
later (2008-2013) years.
Early years 
(n=4350)
Later years 
(n=4063)
P-value
Age 63±13 64±13 0.001
Gender (women) 1165 (27%) 1154 (28%) 0.10
Observed Tako Tsubo 
cardiomyopathy
13 (0.3%) 27 (0.7%) 0.007
BMI (kg/m2) 27±5 28±8 0.20
History of
   MI 441 (10%) 412 (10%) 0.88
   CABG 156 (4%) 135 (3%) 0.56
   PCI 356 (8%) 414 (10%) 0.001
   Stroke 129 (3%) 134 (3%) 0.36
   Diabetes 508 (12%) 458 (11%) 0.59
   Hypertension 1454 (34%) 1557 (37%) <0.001
Positive family history 1710 (42%) 1413 (37%) <0.001
Smoking (ever) 1925 (46%) 1557 (39%) <0.001
Hypercholesterolemia 958 (23%) 840 (22%) 0.07
Killip class >2 on admission 302 (7%) 283 (10%) <0.001
Hospital stay (days) 4±6 5±8 <0.001
Heart frequency (min) 76±18 76±19 0.023
Systolic blood pressure at 
admittance (mmHg)
133±25 132±27 0.70
Diastolic blood pressure at 
admittance (mmHg)
80±16 80±23 0.78
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Table 2
Comparison of clinical characteristics between patients with and without Tako 
Tsubo cardiomyopathy in 8413 patients admitted with STEMI.
Patients without 
Tako Tsubo 
cardiomyopathy
n=8371
Patients with
Tako Tsubo 
cardiomyopathy 
n=42
p-value
Age 63±13 66±13 0.13
Gender (women) 2285 (27%) 34 (81%) <0.001
BMI (kg/m2) 28±13 25±4 0.22
History of
   MI 850 (10%) 3 (7%) 0.54
   CABG 291 (4%) 0 (0%) 0.23
   PCI 769 (9%) 1 (2%) 0.13
   Stroke 261 (3%) 2 (5%) 0.53
   Diabetes 963 (12%) 3 (7%) 0.40
   Hypertension 2999 (36%) 12 (29%) 0.35
Pos family history 3113 (39%) 10 (25%) 0.08
Smoking (ever) 3477 (43%) 5 (12%) <0.001
Hypercholesterolemia 1792 (22%) 6 (15%) 0.24
Killip class ≥ 2 on admission 582 (8%) 3 (9%) 0.80
Hospital stay (days) 4±7 3±3 0.21
Heart frequency (min) 76±21 83±15 0.04
Systolic blood pressure at 
admittance (mmHg)
133±27 135±29 0.47
Diastolic blood pressure at 
admittance (mmHg)
76±19 80±15 0.90
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Figuur 1
Percentage of observed Tako Tsubo presenting as STEMI.
Figuur 2
Amounth of publications in pubmed with Tako Tsubo in the title.
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The findings of the studies presented in this thesis give some answers 
about gender and age related features in patients with STEMI, but there 
are also many things still unclear. The incidence of STEMI in women is 
still high, even after decades of anti-smoke and lifestyle campaigns with 
better treatment of hypertension, diabetes and hypercholesterolemia. 
Myocardial infarction rates have not declined over the last decade in young 
patients, especially not in women (1). Furthermore, even after nationwide 
performing of primary PCI, with improvements in both stent techniques 
and antithrombotic medication, there is ample evidence that prognosis 
improved remarkably in older patients, but not in younger patients (2). 
So, research in STEMI should and must be continued, particularly for 
younger women with STEMI.
Presentation of women with STEMI
Women with STEMI more often present with ‘atypical’ symptoms 
compared to men and this may be an important reason for the observed 
longer patient delay in women (3). An important reason for the atypical 
symptom presentation is most likely related to the lower prevalence of 
acute epicardial coronary occlusion in women compared to men (4). 
National campaigns have been performed to increase awareness, both 
for patients and health care workers, but unfortunately, with insufficient 
results (5). Symptoms of atypical chest pain are often present in (young) 
women and only a minority will have a STEMI. Since many women 
present their complaints first to their general practitioner, improvements 
in objective diagnostic tests to rule out STEMI should be encouraged. 
There is evidence that high sensitive cardiac troponin increases diagnosis 
of myocardial infarction in women, whereas it has minimal additional 
effect on diagnosing type II myocardial infarction in men (4). Possibly, 
even more sensitive laboratory tests than troponin may be helpful in 
the near future (6). Besides this, primary prevention in (young) women 
should have much more attention, since also in our study the prevalence 
of untreated and modifiable risk factors, especially smoking, in young 
women was high.
Increased mortality in younger women after STEMI 
Our finding that, despite an initial more favorable risk profile, younger 
women have increased mortality after STEMI is alarming. Regarding the 
possible different etiology of STEMI between men and women, we found 
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that younger women with STEMI more often have a myocardial infarction 
with non-obstructive coronary artery disease (MINOCA) compared to 
similarly aged men. Recently it has been studied that in MINOCA, still 
20% of patients had signs of myocardial necrosis (7). So an open coronary 
artery at STEMI, does not implicate a benign course of STEMI. In 
patients with MINOCA, a delayed flow of the coronary arteries has been 
shown at angiography (8), which may be associated with microvascular 
coronary dysfunction (9). Another manifestation of a MINOCA is Tako 
Tsubo Cardiomyopathy (TTC), which is also increasingly acknowledged 
to be associated with microvascular coronary dysfunction. We will discuss 
TTC further in another paragraph. Another proportion of patients with 
MINOCA had signs of myocarditis (7). 
So it is essential to consider multiple potential causes if a patient presents 
with MINOCA. These patients require optimal evaluation, so that specific 
therapies can be considered and prognosis improved (10,11). Future 
studies should be performed using more often advanced intravascular 
diagnostic techniques such as intravascular ultrasound (IVUS) or optical 
coherence tomography (OCT), in these STEMI patients to evaluate the 
optimal individual management. 
Also, young women may have a less favorable response to medication. 
This is of importance, because in many large trials, only a minority 
of young women was included and the knowledge about myocardial 
infarction in young women has been largely extrapolated from studies 
primarily focused on (older) men (12,13). Furthermore, young women 
may withdraw medication more frequently because of side effects and 
repulsion to lifelong treatment (14). 
Another possible reason for the worse prognosis in young women with 
STEMI may be the higher incidence of spontaneous coronary dissections 
(SCAD). We will discuss this in a separate section. However, the occurrence 
of SCAD cannot entirely explain the higher mortality of STEMI in young 
women.
Smoking is particularly in young women a major risk factor for STEMI. 
It has been demonstrated that cessation of smoking results in an improved 
prognosis after STEMI (15,16). We had no data whether in our study 
cessation of smoking was comparable between young women and men. 
Possibly, in the future, cessation of smoking should be an outcome 
indicator for patients with STEMI.
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Gender differences in hyperglycemia and diabetes 
An important risk factor in STEMI in men and women is diabetes. 
Although many previous studies demonstrated a higher prevalence of 
diabetes in elderly women with STEMI with a worse prognosis in women, 
we demonstrated that particularly in younger patients (< 65 years) there 
are no gender differences in the prevalence of diabetes. The occurrence 
of diabetes does not seem to contribute to the increased mortality among 
younger women with STEMI.
We did observe that both diabetes and hyperglycemia were more prevalent 
in older women with STEMI compared to similarly aged men. Since 
hyperglycemia and diabetes are associated with an increased mortality 
after STEMI, this is important for the treatment of older women. 
When a STEMI patient presents with hyperglycemia, it is important 
to distinguish hyperglycemia due to a higher abnormal chronic glucose 
metabolism in (not-yet known) diabetics from hyperglycemia due to 
increased stress, particularly induced by abnormal hemodynamics (17,18). 
Hemodynamic deterioration is sometimes difficult to observe, but has 
major prognostic implications. Particularly in patients with concomitant 
hypertension, use of only blood pressure as sign of hemodynamic 
deterioration has its limitations. So, in women with hyperglycemia there 
should be an increased awareness on abnormal hemodynamics and possible 
causes, such as re-occlusion of an infarct related vessel and mechanic 
complications. In those with hemodynamic deterioration treatment 
should be initiated and medication that can worsen hemodynamics (such 
as calcium channel blockers) should be discontinued.
Although the increased prevalence of diabetes in (older) women with 
STEMI as compared to (older) men with STEMI has been observed in 
many previous studies, it is remarkable. In the general elderly population 
the prevalence of diabetes is comparable or even higher in men (19). 
Possibly, women with diabetes have a higher risk of myocardial infarction 
than men with diabetes, although this is debated in the literature (20-
22). However, there is increasing evidence that the impact of vascular and 
myocardial damage of diabetes differs between women and men (23). In 
diabetic women with STEMI, there should be a more aggressive treatment 
of risk factors to prevent recurrence of MI. Future studies have to assess 
whether treatment strategies between men and women with diabetes 
should be different.
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Early menarche as a risk factor for STEMI
We observed that hormonal factors influence the risk of STEMI, as women 
with lower age at menarche had a STEMI at a younger age. As a first step, 
early menarche should be evaluated more often in women presenting with 
a STEMI, to evaluate its importance as a potential female-specific risk 
factor. 
In a population-based study, the incidence of cardiovascular disease was 
increased in women with early menarche (24). Early menarche is an 
important clinical characteristic occurring early in life, which may reveal 
a higher risk of STEMI in later life. It is important to note that current 
Western populations are at higher CVD risk than those decades ago, 
with a shift towards an earlier age at menarche (25). This provides an 
opportunity to use early menarche as an additional risk factor in women 
in combination with other indicators for an increased risk for ischemic 
heart disease. Ultimately, future studies should investigate whether more 
aggressively monitoring and treating risk factors such as smoking, diabetes, 
hypertension and hypercholesterolemia in women with early menarche is 
cost effective. 
Apart from the clinical importance of our findings, more basic research 
should be performed on the mechanisms involved in early menarche and 
myocardial infarction at young age.
Treatment of Spontaneous Coronary Artery Dissection
Spontaneous Coronary Artery Dissection (SCAD) is a relative rare 
observation in patients with STEMI (26,27). However, in young women 
with STEMI the prevalence is much higher than in men, with a prevalence 
rate up to 10% (28). 
There are various studies investigating the etiology of SCAD, suggesting 
that connective tissue disorders such as fibromuscular dysplasia or Ehlers-
Danlos syndrome are associated with SCAD (29). It should be further 
investigated whether all patients with SCAD should be screened for 
genetic factors related to connective tissue disorders. Furthermore, it is 
the question whether this has therapeutic consequences.
We observed that primary PCI in SCAD was more often unsuccessful. 
Although intracoronary visualization with OCT  or IVUS  can better 
visualize the characteristics of the culprit coronary lesion and may identify 
the type and extend of SCAD (24), these techniques have also risks. It 
is therefore recommended to concentrate these invasive procedures in 
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experienced invasive cardiology centers. It is not known whether these 
techniques will lead to improved treatment choices in SCAD patients and 
if this possible benefit justifies the risk of inserting a bulky catheter in a 
dissected artery. This should be the aim of future research.
Because of the relative low incidence of SCAD, multi-center prospective 
studies are needed. After the acute event, it is unclear if either continued 
conservative treatment, or PCI with stenting or bypass surgery (if 
appropriate) are optimal strategies for this patient group, resulting in the 
best long-term prognosis. 
Most SCAD patients receive statins, acetylsalicylic acid, beta blockers and 
ACE-inhibitors, but it is unknown whether these drugs are beneficial. 
Moreover, signs of atherosclerosis are only present in a minority of these 
young patients. Particularly in young women, it is the question whether 
life-long use of standard ACS medication improves their prognosis. This 
should be another topic of future research.
Increased awareness and gender differences in Tako Tsubo 
Cardiomyopathy
Since the first report of TTC was published in the literature in 1991, 
TTC has gained much awareness (30). This was probably augmented 
by an increased number of scientific studies on TTC in the literature 
(31). Furthermore, TTC is increasingly diagnosed, since left ventricular 
imaging in/direct after STEMI is much more customary (32). While 
in the early years predominantly case reports on TCC were published 
(33), in the last decade several national registries with a large number of 
patients have been published (34,35). Dutch hospitals can and should also 
participate in the international registry (36).
There are still many uncertainties regarding the different mechanisms 
involved in TTC in men and women. They respond differently to stress 
and this may importantly contribute to the observed gender differences in 
TTC. Men more often present with physical triggers while women more 
often present with emotional triggers for TTC (37,38). 
Furthermore, an important hypothesis for the mechanism of TTC is 
that microvascular dysfunction and subsequently myocardial stunning 
causes TTC (36, 39). Microvascular dysfunction is more often seen in 
elderly women with ACS than in men (40,41) and possibly, women have a 
predisposition for TTC because of the higher prevalence of micovascular 
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dysfunction. Prospective studies should focus on differences in mechanism 
of TTC between genders and on techniques to enhance microvascular 
perfusion in TTC patients. 
Concluding, women with STEMI differ in many aspects from their male 
counterparts, related to differences in presentation, etiology, risk factors 
and outcome. They may even respond differently to (medical) treatment. 
Prospective, sex-specific studies should be performed to elucidate these 
differences. The current thesis is a small step in our better understanding 
of myocardial infarction in women. 
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Myocardial infarction and particularly ST-Elevation Myocardial 
Infarction (STEMI), is among the most serious presentations of ischemic 
heart disease. Although there are many similarities between women 
and men with STEMI, they have different cardiovascular risk profiles, 
different clinical and angiographic presentation and different outcomes 
after STEMI. Therefore, treatment strategies vary between women and 
men. So, gender differences are important to acknowledge, with ultimately 
consequences for a gender specific management of STEMI. In this thesis, 
several aspects of the difference between women and men with STEMI 
are investigated.
In Chapter 2 we described that the presentation of STEMI in men and 
women often is different. Women present more often with less typical 
symptoms. This atypical presentation is probably the most important 
reason for the longer patient delay in women compared to men with 
a STEMI. This may contribute to a significantly worse prognosis in 
women. However, it has been still unclear whether the potential different 
prognosis between men and women is age dependent. 
To assess whether prognosis in patients with STEMI is different between 
men and women and whether this is age-dependent, we studied in 
Chapter 3, 6746 STEMI patients. Age was stratified into 2 groups, < 
65 years (young group) and ≥ 65 years (elderly). At angiography, single 
vessel disease and normal coronary flow before Percutaneous Coronary 
Intervention (PCI) were more present in younger women than in younger 
men, whereas these differences were not found in the older age group. 
Compared to younger men, younger women had a higher mortality at 
both 30-days (HR 2.1, 95%CI 1.3-3.4) and at 1-year (HR 1.7, 95%CI 
1.2-2.6), whereas in the older age group women had a higher mortality 
at 30-days (HR 1.5, 95%CI 1.1-2.0) but not at 1-year (HR 1.2, 95%CI 
0.9-1.5). We concluded that differences in mortality between men and 
women with STEMI are age-dependent. This may be surprising, since 
younger women had less obstructive coronary artery disease and more 
often normal coronary flow before PCI, suggesting a lower risk STEMI. 
Women had a longer patient delay compared to men, but this was not 
associated to gender-specific mortality.
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Diabetes is not only a risk factor for developing STEMI, but diabetic 
STEMI patients also have a worse prognosis. Many studies have reported 
gender differences in the prevalence of diabetes in patients with STEMI. 
However, it has not been studied whether these differences can be 
observed in both younger and older patients with STEMI. In Chapter 
4, we studied 4640 patients (28% women) with STEMI and examined 
whether the prevalence of either diabetes or hyperglycemia on admission 
was different between various age groups of men and women. The 
prevalence of diabetes was comparable between women and men in the 
younger (<65 years) age group (14% vs 12%, p=0.52), whereas in the older 
age group diabetes was more prevalent in women (25% vs 17% p<0.001). 
In patients without diabetes, admission glucose was comparable between 
both genders in younger patients (8.1±2.0mmol/l vs 8.0±2.2mmol/l 
p=0.36), but in older patients admission glucose was higher in women 
than in men (8.7±2.1mmol/l vs 8.4±2.1mmol/l p=0.028). This difference 
remained after multivariable analyses. Both diabetes and hyperglycemia 
were associated with a higher one-year mortality in both men and 
women. In conclusion, we observed differences in the occurrence of both 
hyperglycemia and diabetes between men and women in older patients, 
with a higher prevalence in older women. 
Next to the traditional cardiovascular risk factors, reproductive risk 
factors may be associated with the risk of ischemic heart disease. Thus 
far the association of these reproductive risk factors with STEMI have 
been poorly investigated. In Chapter 5, we investigated whether early 
menarche is associated with the occurrence of STEMI at younger age. 
Reproductive information was obtained in 688 women with age at STEMI 
<75 years. Younger age of STEMI was defined as STEMI below 60 years 
and was observed in 50% of the patients who returned the questionnaire. 
Age at menarche was categorized as ≤12 years, 13 years, 14 years and ≥15 
years. Younger age at menarche was associated with a higher prevalence 
of smoking. All other classical risk factors for cardiovascular disease 
were comparable between the four groups. After both unadjusted and 
multivariable analysis, women with a lower age at menarche had a higher 
probability of STEMI at younger age, with the adjusted OR 1.6 (95% CI 
1.0-2.6) for age <12 years compared to age ≥15 years. These results suggest 
that younger age at menarche is a risk factor for STEMI at a younger age.
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Spontaneous coronary artery dissection (SCAD) is a relative rare cause of 
myocardial infarction, although it is more common in younger women. 
Since treatment may be more difficult in SCAD as cause of STEMI, and 
there are limited data available in the literature about outcome of primary 
PCI in patients with SCAD, we investigated treatment strategies in SCAD 
in young women. In Chapter 6, we described 263 women < 50 years with 
STEMI. In this group, SCAD was observed in 26 patients (10%). Baseline 
characteristics, including smoking were comparable between women with 
and without SCAD. Women with SCAD were more often conservatively 
treated than women without SCAD (31% vs. 7%, p<0.001). Probably the 
most important finding was that primary PCI in patients with SCAD is less 
effective to restore normal coronary flow. This resulted in less common 
normal coronary flow after the procedure in women with SCAD (73% vs. 
95%, p<0.001). 
Although it is well known that Tako Tsubo cardiomyopathy (TTC) is 
more prevalent in women, it was not yet known in the literature whether 
this gender difference can be observed in both younger and older age 
groups. In Chapter 7 10166 STEMI patients were studied, of whom a 
total of 43 patients (0.4 %) had TTC. In the total cohort, women were 
older, women had less frequently a history of myocardial infarction, 
CABG or PCI, and women were less often smokers. Women had a higher 
prevalence of diabetes and hypertension. In the TTC group, there were 
more women than men (74% vs 26%, adjusted OR 10.7, 95% CI 5.1-
22.4). The prevalence of smoking was lower in both men and women with 
TTC, the prevalence of hypertension was only lower in men with TTC 
compared to men without TTC. All other risk factors between patients 
with and without TTC were comparable in both men and women. The 
most interesting finding of our analysis was that men with TTC were 
younger than men without TTC (50 vs. 62 years, p=0.004), but that this 
age difference was not observed in women (70 vs. 67 years, p=0.18). 
Tako Tsubo cardiomyopathy is a relative new diagnosis, since it was 
first described in 1991. In Chapter 8, we studied potential changes in 
the incidences of TTC over time in patients presenting with STEMI in 
Zwolle. Early years were defined as January 2002 until December 2007 
(n=4350) and later years were defined as January 2008 until December 
2013 (n=4063). Although there were small differences between the two 
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time periods regarding baseline characteristics, in general the two cohorts 
were comparable. Tako Tsubo was more often diagnosed in later years 
(0.7% vs 0.3%, p=0.009), also after correcting for differences in baseline 
characteristics (OR 2.1, 95% CI 1.1-4.3). Probably, the increased incidence 
of TTC in patients with STEMI is due to increased awareness among 
doctors. 

Chapter 11
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Het myocardinfarct en in het bijzonder het ST-Elevatie Myocard Infarct 
(STEMI), is één van de meest ernstige presentaties van ischemische hart- 
ziekte. Hoewel er veel overeenkomsten zijn tussen vrouwen en mannen 
met een STEMI, bestaan er ook veel verschillen, zoals verschillende 
cardiovasculaire risicoprofielen, verschillende klinische- en angiografische 
bevindingen en verschillende uitkomsten na STEMI. Daarom zouden 
er wellicht ook verschillende behandelingsstrategieën voor vrouwen 
en mannen moeten zijn. Kennis van de verschillen tussen mannen en 
vrouwen met STEMI is echter nog beperkt. Meer inzicht in de verschillen 
tussen mannen en vrouwen met een STEMI is daarom van belang, voor 
het uiteindelijk ontwikkelen van sekse specifieke behandeling van STEMI. 
In dit proefschrift worden enkele studies beschreven omtrent verschillen 
tussen vrouwen en mannen met STEMI.
In Hoofdstuk 2 wordt beschreven dat de klinische presentatie van STEMI 
bij mannen en vrouwen vaak verschillend is. Vrouwen presenteren zich 
vaker met minder typische symptomen. Deze atypische presentatie is 
waarschijnlijk de belangrijkste reden dat vrouwen een langere tijd nodig 
hebben om medische hulp te zoeken vergeleken met mannen. Dit kan bij- 
dragen aan een significant slechtere prognose bij vrouwen. Het is echter 
nog steeds onduidelijk of de verschillende prognose tussen mannen en 
vrouwen afhankelijk is van de leeftijd.
Om te beoordelen of de prognose bij patiënten met STEMI verschillend is 
tussen mannen en vrouwen en of dit afhankelijk is van de leeftijd, werden 
in Hoofdstuk 3 6746 STEMI patiënten bestudeerd. De leeftijd werd 
gestratificeerd in 2 groepen, <65 jaar (jonge groep) en ≥ 65 jaar (ouderen). 
Bij angiografie was één vatslijden en normale coronaire doorstroming 
vóór eventuele Percutane Coronaire Interventie (PCI) vaker aanwezig 
bij jongere vrouwen dan bij jongere mannen. Deze verschillen tussen 
mannen en vrouwen werden niet gevonden in de oudere leeftijdsgroep. 
In vergelijking met jongere mannen, hadden jongere vrouwen een hogere 
mortaliteit na zowel 30-dagen (HR 2,1, 95% BI 1,3-3,4) als na 1 jaar (HR 
1,7, 95% BI 1,2-2,6), terwijl in de oudere leeftijdsgroep vrouwen een 
hogere mortaliteit hadden na 30 dagen (HR 1,5, 95% BI 1,1-2,0), maar niet 
na 1 jaar (HR 1,2, 95% BI 0,9-1,5). We concludeerden dat de verschillen 
in sterfte tussen mannen en vrouwen met STEMI leeftijdsafhankelijk 
zijn. Dit is een verrassend resultaat, omdat jongere vrouwen minder 
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obstructieve coronaire hartziekte hadden met vaker normale coronaire 
doorstroming voor PCI. Deze kenmerken duiden op een lager risico 
STEMI. Vrouwen hadden wel een langere tijd nodig om medische hulp 
te zoeken in vergelijking met mannen, maar dit verschil kon de hogere 
sterfte bij vrouwen niet volledig verklaren. 
Diabetes is niet alleen een risicofactor voor het ontwikkelen van STEMI, 
diabetische STEMI patiënten hebben tevens een slechtere prognose. Veel 
studies hebben sekseverschillen in de prevalentie van diabetes bij patiën- 
ten met STEMI genoemd. Er is echter niet onderzocht of deze verschillen 
kunnen worden waargenomen bij zowel jongere als oudere patiënten met 
STEMI. In Hoofdstuk 4 onderzochten we 4640 patiënten (28% vrou- 
wen) met STEMI, waarbij we keken of de prevalentie van diabetes en hyper- 
glykemie bij opname varieerde tussen mannen en vrouwen in verschillende 
leeftijdsgroepen. De prevalentie van diabetes was vergelijkbaar tussen 
vrouwen en mannen in de jongere (<65 jaar) leeftijdsgroep (14% vs 12%, 
p=0,52), terwijl in de oudere leeftijdsgroep diabetes vaker voorkwam bij 
vrouwen (25% versus 17%, p<0,001). Bij patiënten zonder diabetes, was 
het glucose bij opname vergelijkbaar tussen beide geslachten bij jongere 
patiënten (8,1 ± 2,0 mmol/l vs 8,0±2,2 mmol/l, p=0,36), terwijl bij oudere 
patiënten het glucose bij opname hoger was bij vrouwen dan bij mannen 
(8,7±2,1 mmol/l vs 8,4±2,1 mmol/l, p=0,028). Dit verschil bleef aanwezig na 
multivariate analyse. Zowel diabetes als hyperglykemie waren geassocieerd 
met een hogere één-jaar mortaliteit bij zowel mannen als vrouwen. 
Concluderend, toonden we verschillen aan in het voorkomen van zowel 
hyperglykemie en diabetes tussen mannen en vrouwen bij oudere patiën- 
ten (met een hogere prevalentie bij oudere vrouwen geobserveerd), terwijl 
bij jongere patiënten er geen verschil kon worden aangetoond tussen 
mannen en vrouwen.
Naast de traditionele cardiovasculaire risicofactoren, kunnen reproductieve 
risicofactoren geassocieerd zijn met het risico op ischemische hart- 
ziekte. Deze reproductieve risicofactoren zijn in relatie tot STEMI 
weinig onderzocht. In Hoofdstuk 5 hebben we onderzocht of een 
eerste menstruatie (menarche) op jongere leeftijd geassocieerd is met het 
optreden van STEMI op jongere leeftijd. Reproductieve informatie werd 
verkregen van 688 vrouwen, die ten tijden van STEMI jonger waren dan 
75 jaar. Jongere leeftijd bij STEMI werd gedefinieerd als STEMI onder 
142
11
60 jaar en werd bij 50% van de patiënten vastgesteld. De leeftijd bij 
menarche werd ingedeeld als ≤12 jaar, 13 jaar, 14 jaar en ≥15 jaar. Jongere 
leeftijd bij menarche was geassocieerd met een hogere prevalentie van 
roken ten tijde van het STEMI. Alle andere klassieke risicofactoren voor 
hart- en vaatziekten waren vergelijkbaar tussen de vier groepen. Na zowel 
uni- en multivariaat analyse, hadden vrouwen met een lagere leeftijd bij 
menarche een hogere kans op STEMI op jongere leeftijd, (multivariaat 
OR 1,6 95% BI 1,0-2,6) voor de leeftijd <12 jaar in vergelijking met de 
leeftijd ≥15 jaar. Deze resultaten suggereren dat jongere leeftijd van de 
menarche een risicofactor is voor STEMI op jongere leeftijd.
Spontane coronaire arteriële dissectie (SCAD) is een relatief zeldzame 
oorzaak van een hartinfarct, het komt echter het vaker voor bij jongere 
vrouwen. Aangezien de behandeling in SCAD als oorzaak van STEMI 
moeilijker kan zijn en er slechts beperkte gegevens beschikbaar zijn in de 
literatuur over de uitkomst van de primaire PCI bij patiënten met SCAD, 
onderzochten we behandelingsstrategieën in SCAD bij jonge vrouwen. In 
Hoofdstuk 6, beschreven we 263 vrouwen < 50 jaar met een STEMI. In 
deze groep werd SCAD geobserveerd bij 26 patiënten (10%). Kenmerken 
zoals roken waren vergelijkbaar tussen vrouwen met en zonder SCAD. 
Vrouwen met SCAD werden vaker conservatief behandeld dan vrouwen 
zonder SCAD (31% vs 7%, p < 0,001). De belangrijkste bevinding was dat 
primaire PCI bij patiënten met SCAD minder vaak een normale coronaire 
doorstroming herstelde. Normale doorstroming na de procedure van 
vrouwen met SCAD kwam daardoor minder vaak voor (73% vs 95%, 
p<0,001).
Hoewel het algemeen bekend is dat Tako Tsubo Cardiomyopathie (TTC) 
vaker voorkomt bij vrouwen, is het nog niet in de literatuur bekend of 
dit sekse verschil kan worden waargenomen op zowel jongere als oudere 
leeftijd. In Hoofdstuk 7 werden 10166 STEMI patiënten onderzocht, 
waarvan in totaal 43 patiënten (0,4%) TTC hadden. In het totale cohort 
waren vrouwen ouder, rookten minder vaak en hadden minder vaak een 
voorgeschiedenis van myocardinfarct, CABG of PCI. Vrouwen hadden 
een hogere prevalentie van diabetes en hypertensie. De TTC groep, 
bestond uit meer vrouwen dan mannen (74% vs 26%, multivariaat OR 
10.7, 95% BI 5,1-22,4). De prevalentie van het roken was lager bij zowel 
mannen als vrouwen met TTC, de prevalentie van hypertensie was alleen 
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lager bij mannen met TTC in vergelijking met mannen zonder TTC. 
Alle andere risicofactoren tussen patiënten met en zonder TTC waren 
vergelijkbaar in zowel mannen als vrouwen. De meest interessante 
bevinding van onze analyse was dat mannen met TTC jonger zijn dan 
mannen zonder TTC (50 vs 62 jaar, p=0,004), maar dit leeftijdsverschil 
niet werd waargenomen bij vrouwen (70 vs 67 jaar, p = 0,18).
Tako Tsubo Cardiomyopathie is een relatief nieuwe diagnose, die voor 
het eerst werd beschreven in 1991. In Hoofdstuk 8 onderzochten we 
potentiële veranderingen in de incidentie van TTC in de tijd bij patiënten 
met een STEMI in Zwolle.  De vroege jaren werden gedefinieerd als ja- 
nuari 2002 tot december 2007 (n=4350) en late jaren werden gedefinieerd 
als januari 2008 tot december 2013 (n=4063). Hoewel er kleine verschillen 
waren tussen de twee periodes met betrekking tot algemene patiënten 
kenmerken, waren in het algemeen de twee cohorten vergelijkbaar. 
Tako Tsubo werd vaker gediagnosticeerd in de late jaren (0,7% vs 0,3%, 
p=0,009), ook na correctie voor verschillen in de patiënten karakteristieken 
(OR 2.1, 95% BI 1,1-4,3). Waarschijnlijk is de verhoogde incidentie van 
TTC bij patiënten met STEMI veroorzaakt doordat dat artsen zich meer 
bewust zijn van de diagnose TTC en deze daardoor vaker stellen.
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en gedachten erachter liggen en dat is onbetaalbaar. Dank je wel daarvoor. 
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Lieve Sander, met jou in mijn leven, ben ik een heel erg gelukkige vrouw. 
Je hebt me zonder protest ontelbare avonden laten werken. Aan de andere 
kant laat je mij, als ik hierin doorschiet, realiseren dat het ook relaxter 
kan. Ik heb ontzettend veel van jou geleerd tijdens het maken van dit 
proefschrift. Je gaf mij altijd steun, tijd en ruimte. Met dit boekje hebben 
we een kroon op alweer een fantastische periode gezet. Ik heb er enorm 
zin in om met jou de rest van m’n leven papa en mama te zijn.
Amber M. Otten
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Master of Science in Clinical Research
Netherlands Institute for Health Sciences
Postgraduate Research Training (international degree programme 
Erasmus MC)
Overview MSc:
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(2009-2015) thesis: age and gender related differences in STEMI patients 
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AHEM. Predictors and prognosis of spontaneous coronary artery 
dissection in young women presenting with STEMI.
o NVVC 2012. Netherlands heart journal
 
158
13
Appendix
Courses followed
Summer and winter programmes Erasmus MC 
Principles of Research in Medicine and Epidemiology 2006
Methods of Clinical Research 2006
Pharmaco-epidemiology 2006
Introduction to Decision-making in Medicine 2006
Topics in Evidence-based Medicine 2006
Clinical Trials  2006
Regression Analysis  2007
Topics in Meta-analysis  2007
Survival Analysis 2008
Case-control Studies 2008
Introduction to Data-analysis 2008
Demography of Ageing  2008
Core courses
Study Design 2006
 
Elective courses 
Modern Statistical Methods 2007
Broad orientation - 2nd year elective 2009
 
Advanced Courses 
Introduction to Clinical Research 2007
Advanced Topics in Decision-making in Medicine 2007
Intervention Research and Clinical Trial 2007
Prognosis Research 2007
Research Themes and Methodologies 2007
Diagnostic Research 2007
Repeated Measurements in Clinical Studies 2009
Advanced Topics in Clinical Trials 2009
Analysis of Time-varying Exposures 2009
Advanced Analysis of Prognosis Studies 2009
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Skill oriented courses 
A First Glance at SPSS for Windows 2007
Working with SPSS for Windows 2007
 
International courses at Johns Hopkins University 
Genetic epidemiology in populations 2008
Nutritional epidemiology 2008
Public health dimensions of global tuberculosis control 2008
Topics in infectious disease epidemiology 2008
ACS masterclass 8-9 september 2011 at Geneve.
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